ABT-737

Name: ABT-737
Brand: Selleck Chemicals
SKU: S1002
Rating: 5 (307 reviews)

For research use only.

Catalog No.S1002

307 publications

CAS No. 852808-04-9

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. ABT-737 induces mitochondrial pathway apoptosis and mitophagy. Phase 2.

Selleck's ABT-737 has been cited by 307 publications

Cell, 2018, 175(2):429-441

PubMed: 30245008 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):435-449

PubMed: 29533784 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Nat Methods, 2017, 14(9):891-896

PubMed: 28737741 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Nat Med, 2013, 19(11):1478-88

PubMed: 24141421 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(6):542-6

PubMed: 21623355 ( click the link to review the publication )

Adv Biol Regul, 2021, S2212-4926(20)30091-9

PubMed: 33451973 ( click the link to review the publication )

Commun Biol, 2021, 4(1):20

PubMed: 33398046 ( click the link to review the publication )

ACS Nano, 2020, 14(3):3378-3388

PubMed: 32083466 ( click the link to review the publication )

Sci Adv, 2020, 6(47)eabc3465

PubMed: 33208362 ( click the link to review the publication )

Nat Commun, 2020, 11(1):259

PubMed: 31937780 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

EMBO J, 2020, e105071

PubMed: 32840892 ( click the link to review the publication )

Cancer Res, 2020, 10.1158/0008-5472.CAN-19-1784

PubMed: 32005716 ( click the link to review the publication )

Elife, 2020, 2;9:e54954

PubMed: 32484436 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(2) pii: E406

PubMed: 32050632 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0756

PubMed: 33334730 ( click the link to review the publication )

Development, 2020, 147(22)dev194555

PubMed: 33028610 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.510.2019

PubMed: 32371581 ( click the link to review the publication )

Allergy Asthma Immunol Res, 2020, 12(4):608-625

PubMed: 32400128 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Mol Biosci, 2020, 7:566291

PubMed: 33425984 ( click the link to review the publication )

Sci Rep, 2020, 20;10(1):687

PubMed: 31959760 ( click the link to review the publication )
Cancer Cell Int, 2020, 20:405

PubMed: 32863764 ( click the link to review the publication )

Biomed Pharmacother, 2020, 126:110040

PubMed: 32145585 ( click the link to review the publication )

Ann Transl Med, 2020, 8(6):364

PubMed: 32355808 ( click the link to review the publication )

Eur J Pharm Sci, 2020, 142:105105

PubMed: 31669390 ( click the link to review the publication )

Platelets, 2020, 10.1080/09537104.2020.1724276

PubMed: 32079453 ( click the link to review the publication )

Cell Death Differ, 2020, 10.1038

PubMed: 32015503 ( click the link to review the publication )

Environ Toxicol, 2020, 10.1002

PubMed: 32061152 ( click the link to review the publication )

Cell Rep, 2020, 32(1):107845

PubMed: 32640215 ( click the link to review the publication )

Life Sci Alliance, 2020, 28;3(6) pii: e202000735

PubMed: 32345661 ( click the link to review the publication )

Transfusion, 2020, 60(4):806-814

PubMed: 32159862 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0234103

PubMed: 32645016 ( click the link to review the publication )

Infect Immun, 2020, 10.1128/IAI.00851-19

PubMed: 32179584 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

STAR Protoc, 2020, 1(1)100034

PubMed: 32793892 ( click the link to review the publication )

Cell Death Dis, 2020, 11(1):8

PubMed: 31907357 ( click the link to review the publication )

Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5770

PubMed: 31852899 ( click the link to review the publication )

EMBO J, 2019, 15;38(10):e101638

PubMed: 30902848 ( click the link to review the publication )

EMBO J, 2019, 38(11)

PubMed: 30979778 ( click the link to review the publication )

Dev Cell, 2019, 51(2):277-291

PubMed: 31564612 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2339-2351

PubMed: 30862722 ( click the link to review the publication )

Cell Rep, 2019, 27(12):3657-3671

PubMed: 31216482 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Elife, 2019, 8e38730

PubMed: 31042147 ( click the link to review the publication )
Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31540244 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31810230 ( click the link to review the publication )

Cell Death Dis, 2019, 10(2):121

PubMed: 30741926 ( click the link to review the publication )

J Cancer, 2019, 10(6):1466-1478

PubMed: 31031856 ( click the link to review the publication )

Thromb Haemost, 2019, 19(10):1665-1674

PubMed: 31493778 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:5820415

PubMed: 31885804 ( click the link to review the publication )

Eur J Immunol, 2019, 10.1002/eji.201948254

PubMed: 31411729 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(4):419-429

PubMed: 31467029 ( click the link to review the publication )

Biochem J, 2019, 476(9):1335-1357

PubMed: 30992316 ( click the link to review the publication )

Phytomedicine, 2019, 64:153068

PubMed: 31419729 ( click the link to review the publication )

Phytomedicine, 2019, 52:147-156

PubMed: 30599894 ( click the link to review the publication )

Life Sci, 2019, 232:116561

PubMed: 31247208 ( click the link to review the publication )

Chem Biol Interact, 2019, 309:108723

PubMed: 31228469 ( click the link to review the publication )

J Bone Oncol, 2019, 19:100268

PubMed: 31832331 ( click the link to review the publication )

J Bone Oncol, 2019, 15:100222

PubMed: 30766792 ( click the link to review the publication )

PLoS One, 2019, 14(12):e0225977

PubMed: 31826021 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:897-906

PubMed: 30774376 ( click the link to review the publication )

Platelets, 2019, 30(1):75-80

PubMed: 29125379 ( click the link to review the publication )

Oncotarget, 2019, 10(58):6219-6233

PubMed: 31692812 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 200(1):84-97

PubMed: 30649895 ( click the link to review the publication )

Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5435

PubMed: 30575733 ( click the link to review the publication )
Clin Cancer Res, 2018, 24(21):5458-5470

PubMed: 30021909 ( click the link to review the publication )

Cell Death Differ, 2018, 25(4):784-796

PubMed: 29229994 ( click the link to review the publication )

Oncogene, 2018, 37(39):5325-5339

PubMed: 29858601 ( click the link to review the publication )

Oncogene, 2018, 37(33):4599-4610

PubMed: 29755130 ( click the link to review the publication )

Cell Mol Life Sci, 2018, 75(14):2663-2680

PubMed: 29396625 ( click the link to review the publication )

Cancers (Basel), 2018, 10(11)E439

PubMed: 30441794 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):994

PubMed: 30250198 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):199

PubMed: 29415991 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 48(3):1123-1138

PubMed: 30041196 ( click the link to review the publication )

Eur J Med Chem, 2018, 159:357-380

PubMed: 30308410 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2018, 1865(3):522-531

PubMed: 29278689 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(6):935-946

PubMed: 29545477 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Sci Rep, 2018, 8(1):15752

PubMed: 30361682 ( click the link to review the publication )

Int J Oncol, 2018, 53(3):1055-1068

PubMed: 30015875 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(6):465-474

PubMed: 29394130 ( click the link to review the publication )

Phytother Res, 2018, 32(6):1126-1134

PubMed: 29464855 ( click the link to review the publication )

Thromb Res, 2018, 171:22-30

PubMed: 30240944 ( click the link to review the publication )

Environ Mol Mutagen, 2018, 59(1):49-59

PubMed: 28843007 ( click the link to review the publication )

Ann Surg Treat Res, 2018, 95(5):240-248

PubMed: 30402442 ( click the link to review the publication )

Oncotarget, 2018, 9(28):20075-20088

PubMed: 29732004 ( click the link to review the publication )
Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

Oncotarget, 2018, 9(39):25630-25646

PubMed: 29876013 ( click the link to review the publication )

Oncotarget, 2018, 9(42):26834-26851

PubMed: 29928488 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1754-1769

PubMed: 28982759 ( click the link to review the publication )

Biomaterials, 2017, 144:73-83

PubMed: 28823845 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2512-2521

PubMed: 28202514 ( click the link to review the publication )

Cell Death Differ, 2017, 24(11):1963-1974

PubMed: 28777375 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 29148970 ( click the link to review the publication )

Oncogene, 2017, 36(15):2066-2073

PubMed: 27694901 ( click the link to review the publication )

Cancer Lett, 2017, 411:19-26

PubMed: 28987383 ( click the link to review the publication )

Sci Signal, 2017, 10(499)

PubMed: 28974650 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Eur J Immunol, 2017, 47(6):1009-1021

PubMed: 28493377 ( click the link to review the publication )

Biochem Pharmacol, 2017, 140:41-52

PubMed: 28595877 ( click the link to review the publication )

J Biol Chem, 2017, 292(36):15105-15120

PubMed: 28673964 ( click the link to review the publication )

Analyst, 2017, 142(23):4399-4404

PubMed: 29116264 ( click the link to review the publication )

Mol Cell Biol, 2017, 37(3)e00535-16

PubMed: 27821478 ( click the link to review the publication )

Clin Immunol, 2017, 181:32-42

PubMed: 28579554 ( click the link to review the publication )

Toxicol In Vitro, 2017, 42:38-46

PubMed: 28366708 ( click the link to review the publication )
Mol Cell Biochem, 2017, 429(1-2):91-102

PubMed: 28120212 ( click the link to review the publication )

Arch Oral Biol, 2017, 73:1-6

PubMed: 27632413 ( click the link to review the publication )

Oncol Lett, 2017, 14(1):903-908

PubMed: 28693250 ( click the link to review the publication )

Asia Pac J Clin Oncol, 2017, 13(2):e144-e152

PubMed: 26552712 ( click the link to review the publication )

Oncotarget, 2017, 8(65):108522-108533

PubMed: 29312548 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Cell Death Dis, 2017, 8(6):e2898

PubMed: 28661475 ( click the link to review the publication )

Oncotarget, 2017, 8(43):74299-74311

PubMed: 29088786 ( click the link to review the publication )

Anat Rec (Hoboken), 2017, 300(2):326-339

PubMed: 27486855 ( click the link to review the publication )

Thromb Haemost, 2017, 117(2):311-324

PubMed: 27929199 ( click the link to review the publication )

Oncotarget, 2017, 8(29):46801-46817

PubMed: 27086916 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28692422 ( click the link to review the publication )

Oncotarget, 2017, 8(5):8670-8678

PubMed: 28055968 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(6):E980-E989

PubMed: 28049849 ( click the link to review the publication )

Viruses, 2017, 9(10)

PubMed: 28946654 ( click the link to review the publication )

J Clin Invest, 2016, 126(1):181-94

PubMed: 26619119 ( click the link to review the publication )

Nat Commun, 2016, 7:11190

PubMed: 27048913 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(5):1138-49

PubMed: 26467384 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1313-9

PubMed: 26759243 ( click the link to review the publication )

Br J Pharmacol, 2016, 173(3):471-83

PubMed: 26493374 ( click the link to review the publication )

Cell Death Dis, 2016, 7(8):e2342

PubMed: 27537525 ( click the link to review the publication )

Br J Cancer, 2016, 114(11):1219-26

PubMed: 27140314 ( click the link to review the publication )

Oncogenesis, 2016, 10.1038/oncsis.2016.33

PubMed: 27159675 ( click the link to review the publication )
J Virol, 2016, 90(5):2356-71

PubMed: 26676786 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1863(4):562-71

PubMed: 26704388 ( click the link to review the publication )

Lab Invest, 2016, 96(10):1128-37

PubMed: 27617402 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(6):1345-57

PubMed: 27429848 ( click the link to review the publication )

Cancer Cell Int, 2016, 16:27

PubMed: 27042160 ( click the link to review the publication )

J Immunother, 2016, 39(3):117-26

PubMed: 26938945 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 477(4):607-13

PubMed: 27343560 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(1):143-148

PubMed: 27449608 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Exp Ther Med, 2016, 11(2):669-673

PubMed: 26893664 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83208-83222

PubMed: 27825124 ( click the link to review the publication )

Sci Rep, 2016, 6:21264

PubMed: 26887909 ( click the link to review the publication )

Oncotarget, 2016, 7(3):3520-32

PubMed: 26657288 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10839-49

PubMed: 26880588 ( click the link to review the publication )

Oncotarget, 2016, 7(51):85492-85501

PubMed: 27863431 ( click the link to review the publication )

Oncotarget, 2016, 7(24):35989-36001

PubMed: 27056884 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6626-38

PubMed: 26675547 ( click the link to review the publication )

Oncotarget, 2016, 7(48):79637-79653

PubMed: 27793034 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84594-84607

PubMed: 27829238 ( click the link to review the publication )

Oncotarget, 2016, 7(47):77815-77824

PubMed: 27780925 ( click the link to review the publication )

Blood, 2015, 24;126(13):1565-74

PubMed: 26254443 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Autophagy, 2015, 11(3):452-9

PubMed: 25715028 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(17):3995-4003

PubMed: 26015514 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2015, 112(6):E536-45

PubMed: 25624498 ( click the link to review the publication )

EMBO Rep, 2015, 16(5):618-27

PubMed: 25739811 ( click the link to review the publication )

Cancer Res, 2015, 75(24):5318-28

PubMed: 26670562 ( click the link to review the publication )

Cancer Res, 2015,

PubMed: 25432173 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.8

PubMed: 25698446 ( click the link to review the publication )

J Med Chem, 2015, 58(4):1644-68

PubMed: 25585174 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: 25308513 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: ( click the link to review the publication )

J Biol Chem, 2015, 290(19):12290-9

PubMed: 25829495 ( click the link to review the publication )

J Biol Chem, 2015, 290(34):20841-55

PubMed: 26124276 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:34

PubMed: 25852302 ( click the link to review the publication )

Neurogastroenterol Motil, 2015, 10.1111/nmo.12521

PubMed: 25690069 ( click the link to review the publication )

Int J Oncol, 2015, 46(2):667-76

PubMed: 25434832 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 70:64-71

PubMed: ( click the link to review the publication )

Eur J Pharm Sci, 2015, 70:64-71

PubMed: 25596561 ( click the link to review the publication )

Exp Cell Res, 2015, 335(1):62-7

PubMed: 26024774 ( click the link to review the publication )

Exp Cell Res, 2015, 10.1016/j.yexcr.2015.04.016

PubMed: 25936772 ( click the link to review the publication )

BMC Cancer, 2015, 15:919

PubMed: 26585594 ( click the link to review the publication )

Chembiochem, 2015, 16(5):757-65

PubMed: 25711460 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143685

PubMed: 26606677 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 464(1):286-91

PubMed: 26116776 ( click the link to review the publication )

Exp Hematol, 2015, 43(3):180-190.e6

PubMed: 25461257 ( click the link to review the publication )

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 10.1016/j.mrfmmm.2015.04.005

PubMed: ( click the link to review the publication )

Cell Biochem Funct, 2015, 33(5):334-40

PubMed: 26178811 ( click the link to review the publication )
Anticancer Res, 2015, 35(3):1803-8

PubMed: 25750346 ( click the link to review the publication )

Anticancer Res, 2015,

PubMed: 26637878 ( click the link to review the publication )

Oncotarget, 2015, 6(26):22624-40

PubMed: 26265439 ( click the link to review the publication )

Oncotarget, 2015, 6(34):36338-53

PubMed: 26462148 ( click the link to review the publication )

Oncotarget, 2015, 6(8):5582-96

PubMed: 25714024 ( click the link to review the publication )

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608 ( click the link to review the publication )

Oncotarget, 2015, 6(1):409-26

PubMed: 25565667 ( click the link to review the publication )

Oncotarget, 2015, 6(34):35667-83

PubMed: 26447615 ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Hepatol Res, 2015, 45(9):1023-1033

PubMed: 25297967 ( click the link to review the publication )

Nat Commun, 2014, 5:5637

PubMed: 25472497 ( click the link to review the publication )

Autophagy, 2014, 10(10):1776-86

PubMed: 25126729 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(21):5446-55

PubMed: 25208882 ( click the link to review the publication )

Leukemia, 2014, 28(10):1960-8

PubMed: 24577530 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Biomaterials, 2014, 16(2):R41

PubMed: 24745479 ( click the link to review the publication )

Cell Death Differ, 2014, 21(7):1170-7

PubMed: 24682005 ( click the link to review the publication )

Cell Death Differ, 2014, 10.1038/cdd.2014.158

PubMed: 25301069 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.09.024

PubMed: 25304383 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Sci Signal, 2014, 7(357):ra122

PubMed: 25538080 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1514

PubMed: 25375379 ( click the link to review the publication )

Biomaterials Science, 2014, 10.1039/C4BM00072B

PubMed: ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )
Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1275

PubMed: 24901046 ( click the link to review the publication )

Acta Neuropathol Commun, 2014, 10.1186/2051-5960-2-57

PubMed: 24887326 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-13-0998

PubMed: 24739394 ( click the link to review the publication )

Mol Cancer Res, 2014, 13(12):3332-42

PubMed: 25154561 ( click the link to review the publication )

Mol Cancer Res, 2014, (4):550-9

PubMed: 24469836 ( click the link to review the publication )

J Immunol, 2014, 193(10):4914-23

PubMed: 25288570 ( click the link to review the publication )

Bone, 2014, 67:166-74

PubMed: 25016096 ( click the link to review the publication )

J Biol Chem, 2014, 289(22):15495-15506

PubMed: 24739390 ( click the link to review the publication )

J Immunother, 2014, 37(1):8-15

PubMed: 24316551 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(11):20500-17

PubMed: 25387078 ( click the link to review the publication )

Int J Cardiol, 2014, 176(3):923-9

PubMed: 25194861 ( click the link to review the publication )

Int J Hyperthermia, 2014, 30(7):502-12

PubMed: 25354679 ( click the link to review the publication )

Cell Cycle, 2014, 10.4161/15384101.2014.973321

PubMed: ( click the link to review the publication )

Thromb Res, 2014, 134(6):1311-5

PubMed: 25288466 ( click the link to review the publication )

Thromb Res, 2014, 133(1):73-9

PubMed: 24268298 ( click the link to review the publication )

PLoS One, 2014, 9(9):e103015

PubMed: 25181509 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84388

PubMed: 24427286 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106571

PubMed: 25192188 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105049

PubMed: 25126950 ( click the link to review the publication )

PLoS One, 2014, 9(3):e91782

PubMed: 24626299 ( click the link to review the publication )

PLoS One, 2014, 9(5):e96733

PubMed: 24824755 ( click the link to review the publication )

Leuk Lymphoma, 2014, 5:1-12

PubMed: 25373508 ( click the link to review the publication )
Biomed Res Int, 2014, 2014:306718

PubMed: ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(11):4321-6

PubMed: 23447565 ( click the link to review the publication )

Cell Death Differ, 2013, 20(11):1532-45

PubMed: 23933817 ( click the link to review the publication )

Mol Cancer, 2013, 12(1):42

PubMed: 23680104 ( click the link to review the publication )

Int J Cancer, 2013, 133(8):1813-24

PubMed: 23580240 ( click the link to review the publication )

J Neurosci, 2013, 33(46):18098-108

PubMed: 24227720 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e702

PubMed: 23828565 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e931

PubMed: 24263105 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e762

PubMed: 23928701 ( click the link to review the publication )

Br J Cancer, 2013, 108(9):1870-8

PubMed: 23558901 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e690

PubMed: 23807219 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e801

PubMed: 24030153 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Br J Haematol, 2013, 163(3):377-84

PubMed: 24033315 ( click the link to review the publication )

Br J Haematol, 2013, 161(2):245-54

PubMed: 23398569 ( click the link to review the publication )

Stem Cells Transl Med, 2013, 2(9):690-702

PubMed: 23934910 ( click the link to review the publication )

Cancer Sci, 2013, 104(6):732-9

PubMed: 23421409 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(2):109-21

PubMed: 23233484 ( click the link to review the publication )

Cancer Gene Ther, 2013, 20(7):386-93

PubMed: 23788110 ( click the link to review the publication )

J Biol Chem, 2013, 288(10):6826-34

PubMed: 23329846 ( click the link to review the publication )

Apoptosis, 2013, 18(11):1403-15

PubMed: 23760752 ( click the link to review the publication )

Biomed Pharmacother, 2013, 67(7):583-91

PubMed: 23706691 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2013, 274(2):319-27

PubMed: 24321340 ( click the link to review the publication )

Int J Biochem Cell Biol, 2013, 45(5):944-51

PubMed: 23395630 ( click the link to review the publication )
PLoS One, 2013, 8(5):e63232

PubMed: 23658815 ( click the link to review the publication )

PLoS One, 2013, 8(11):e78570

PubMed: 24223823 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 437(4):565-72

PubMed: 23850692 ( click the link to review the publication )

Leuk Lymphoma, 2013, 54(2):372-80

PubMed: 22830613 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )

Basic Clin Pharmacol Toxicol, 2013, 113(3):145-51

PubMed: 23557083 ( click the link to review the publication )

J Ovarian Res, 2013, 6(1):72

PubMed: 24103422 ( click the link to review the publication )

Phys Biol, 2013, 10(3):035002

PubMed: 23735516 ( click the link to review the publication )

Cytometry A, 2013, 83(2):227-34

PubMed: 23165976 ( click the link to review the publication )

Oncotarget, 2013,

PubMed: 24334291 ( click the link to review the publication )

Blood, 2012, 120(19):3978-85

PubMed: 22927247 ( click the link to review the publication )

Mol Cell, 2012, 46(5):573-83

PubMed: 22560721 ( click the link to review the publication )

J Clin Invest, 2012, 122(6):2018-31

PubMed: 22622039 ( click the link to review the publication )

EMBO J, 2012, 31(10):2322-35

PubMed: 22510886 ( click the link to review the publication )

Oncogene, 2012, 31(26):3177-89

PubMed: 22056880 ( click the link to review the publication )

Breast Cancer Res, 2012, 14(3):R96

PubMed: 22703841 ( click the link to review the publication )

Anal Chem, 2012, 84(11):4703-10

PubMed: 22533353 ( click the link to review the publication )

Br J Haematol, 2012, 159(5):565-71

PubMed: 23025479 ( click the link to review the publication )

Mol Cancer Res, 2012, 10(3):347-59

PubMed: 22241218 ( click the link to review the publication )

J Biol Chem, 2012, 287(25):21357-70

PubMed: 22553204 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17682-92

PubMed: 22433870 ( click the link to review the publication )

Mol Endocrinol, 2012, 26(9):1508-20

PubMed: 22771494 ( click the link to review the publication )

Phytother Res, 2012, 27(6):835-40

PubMed: 22899281 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )
PLoS One, 2012, 7(8):e43158

PubMed: 22912816 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52333

PubMed: 23284992 ( click the link to review the publication )

J Pharmacol Sci, 2012, 119(4):330-40

PubMed: 22814102 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

J Clin Invest, 2011, 121(3):1053-63

PubMed: 21317538 ( click the link to review the publication )

Leukemia, 2011, 25(11):1728-38

PubMed: 21701487 ( click the link to review the publication )

Neuro Oncol, 2011, 13(12):1265-76

PubMed: 21880625 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370 ( click the link to review the publication )

Oncogene, 2011, 30(37):3918-29

PubMed: 21460857 ( click the link to review the publication )

Am J Nephrol, 2011, 34(6):549-59

PubMed: 22123611 ( click the link to review the publication )

Cancer Chemoth Pharm, 2011, 67(3):557-67

PubMed: 20473610 ( click the link to review the publication )

PLoS One, 2011, 6(6):e20423

PubMed: 21674052 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24102

PubMed: 21949692 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Curr Pharmacogenomics Person Med, 2011, 9(3):184-190

PubMed: 22162984 ( click the link to review the publication )

Mol Cancer Ther, 2010, 19(20):5591-601

PubMed: 20587662 ( click the link to review the publication )

J Biol Chem, 2010, 285(26):19910-20

PubMed: 20421300 ( click the link to review the publication )

Apoptosis, 2010, 15(10):1256-69

PubMed: 20582477 ( click the link to review the publication )

Exp Hematol, 2010, 38(10):908-921

PubMed: 20540984 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Features

First-generation inhibitor of anti-apoptotic Bcl-2 proteins.

Targets

Bcl-2 ^[1] (Cell-free assay)	Bcl-xL ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)	Bcl-B ^[1] (Cell-free assay)
30.3 nM(EC50)	78.7 nM(EC50)	197.8 nM(EC50)	1.82 μM(EC50)

In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. ^[1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. ^[2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. ^[3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. ^[4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
OCI-Ly1	Mne0R4VtdCCYaXHibYxqfHliQYPzZZk>	NYn1cG83OjVyIH7NxsA>	Mn;TO\|IhcA>?	M3vT[GROW09?	MXPjZZV{\WRiOUelJIxwe3Nib3[geoli[mmuaYT5JIlvKGOnbHzzJJRz[W6\|ZnXjeIVlKHerdHigRmNNPiC\|aWLORS=>	NWHlOmxYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVczQDhpPkK2OlU4Ojh6PD;hQi=>
KG1a	NFrFbXBE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NYH1PXM4OC1zMDFOwG0>	MXSyOEBp	Mn35SG1UVw>?	NGPldmRKSzVyPUeuOlgh\|ryPLDDk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NIHCbYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW1NlcyOid-Mk[1OVI4OTJ:L3G+
Kasumi-1	MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M1XhWFAuOTBizszN	MYSyOEBp	NE\uXW5FVVOR	M{DHfGlEPTB;ND64O{DPxE1uIHTlZ5Jm[XOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV3MkexNkc,OjZ3NUK3NVI9N2F-
KG1a	NVjsOZh[SXCxcITvd4l{KEG\|c3H5	NGrGUYYxNTFyIN88US=>	MlXpNlQhcA>?	M2L1RmROW09?	NGH0O2NqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV3MkexNkc,OjZ3NUK3NVI9N2F-
Kasumi-1	MWPBdI9xfG:\|aYOgRZN{[Xl?	MlzyNE0yOCEQvF2=	M{PoPVI1KGh?	NFXLbJFFVVOR	MnnEbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV3MkexNkc,OjZ3NUK3NVI9N2F-
MC-3	NYrs[3lGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzlOU8yOC9{MDFOwG0>	MViyOEBp	M3jxdWROW09?	M2TyRYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M{nmTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NES3OlE2Lz5{NkS0O\|YyPTxxYU6=
HN22	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoG3Nk42NzdwNT:yNk42KM7:TR?=	MkT3NlQhcA>?	MX;EUXNQ	NIDXeFdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR2N{[xOUc,OjZ2NEe2NVU9N2F-
MC-3	MYfBdI9xfG:\|aYOgRZN{[Xl?	NYm4XGI4PS9zMD:yNEDPxE1?	M13se\|I1KGh?	NGPsPYNFVVOR	Mlf6bY5lfWOnczDjZZNx[XOnLX3l[IlifGWmIHHwc5B1d3Orcx?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR2N{[xOUc,OjZ2NEe2NVU9N2F-
HN22	NH;kSnFCeG:ydH;zbZMhSXO\|YYm=	M4m2XlIvPS95LkWvNlIvPSEQvF2=	MnzaNlQhcA>?	MYjEUXNQ	NE[3UmdqdmS3Y3XzJINie3Cjc3WtcYVlcWG2ZXSgZZBweHSxc3nz	NXnlZVNKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0OFc3OTVpPkK2OFQ4PjF3PD;hQi=>
MOLT-4	NF7qSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPGNVAuPTByMDDuUS=>	NITX[Xo4OiCq	Mk\aSG1UVw>?	MUDJR\|UxRTBwMUm4JO69VQ>?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7MkOzNkc,OjZ\|OUKzN\|I9N2F-
RS4;11	NXmyV\|I2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jDS\|ExNTVyMECgcm0>	NIXodoU4OiCq	MVzEUXNQ	NEXhXFdKSzVyPUCuNFAzKM7:TR?=	NW[wdZZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVI{OzJpPkK2N\|kzOzN{PD;hQi=>
JURKAT	NG[0NHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\LTVExNTVyMECgcm0>	M2G4[VczKGh?	M1jqVWROW09?	NH;0VlFKSzVyPU[2JO69VQ>?	MkDnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OUKzN\|IoRjJ4M{myN\|MzRC:jPh?=
CEM R	Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3WSI9ROTBvNUCwNEBvVQ>?	M33EcFczKGh?	MkiwSG1UVw>?	MYfJR\|UxRTVwNDFOwG0>	NYPvfWtpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVI{OzJpPkK2N\|kzOzN{PD;hQi=>
CEM S	NILH[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHHTos6OTBvNUCwNEBvVQ>?	MXi3NkBp	MkHuSG1UVw>?	MYrJR\|UxRTF{LkGg{txO	NI\3VZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5NlM{Oid-Mk[zPVI{OzJ:L3G+
MOLT-4	MmPJRZBweHSxc3nzJGF{e2G7	MVWxNE0yODByIH7N	MYOyOEBp	M{jV[GROW09?	M17vTYNifXOnczD0bIUh[2ynYY\h[4Uhd2ZiQnPsMVIh[W6mIITo[UBld3ewcnXneYxifGmxbjDv[kBD[2xveFygZY5lKE2lbD2x	M3\YTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{myN\|MzLz5{NkO5NlM{OjxxYU6=
CEM S	NXP5UFVSSXCxcITvd4l{KEG\|c3H5	M1;ablExNTFyMECgcm0>	MVqyOEBp	M2\YZmROW09?	NIX0TXdk[XW\|ZYOgeIhmKGOuZXH2ZYdmKG:oIFLjcE0zKGGwZDD0bIUh\G:5boLl[5Vt[XSrb36gc4YhSmOuLYjMJIFv\CCPY3ytNS=>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7MkOzNkc,OjZ\|OUKzN\|I9N2F-
JURKAT	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVWxNFAuOTByMDDuUS=>	MU[0PEBp	M1PnOmROW09?	Mn\hTWM2OD17NUZCtVkvOyCwTR?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF5MkK2PUc,OjZzN{KyOlk9N2F-
LOUCY	NXLscnA{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEK1bJAyODBvMUCwNEBvVQ>?	NGjwT\|M1QCCq	MkDpSG1UVw>?	M1TwRmlEPTB;M{KuPOKyOTBwOTDuUS=>	NIjmOZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG3NlI3QSd-Mk[xO\|IzPjl:L3G+
WM-115	MnfMR4VtdCCYaXHibYxqfHliQYPzZZk>	M1OyeFExOMLibl2=	MlniO\|IhcA>?		NETSR3BmdmijbnPld{BkfXKldX3pck1qdmS3Y3XkJIFvfGlvc4Xyeol3[W{EoB?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzNke3Okc,OjZzMU[3O\|Y9N2F-
B16	MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MoPyNVAxyqCwTR?=	MVS3NkBp		M{S1ZoVvcGGwY3XzJIN2emO3bXnuMYlv\HWlZXSgZY51cS2\|dYL2bZZidMLi	NFf4RWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxOlc4Pid-Mk[xNVY4PzZ:L3G+
HL-60	NYHuVmMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2TsfFczKGh?		MWLJR\|UxyqB;IEGwMlchdk1?	MojCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNEW2NFkoRjJ4MES1OlA6RC:jPh?=
MOLM-13	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NI\OcZg4OiCq		M2LM[2lEPTEEoE2gNlcvQSCwTR?=	M1;6V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MES1OlA6Lz5{NkC0OVYxQTxxYU6=
OCI-AML3	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1jt[\|czKGh?		Mn7vTWM2OMLiPTCxPVUxKG6P	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2NU[wPUc,OjZyNEW2NFk9N2F-
BCWM.1	NV[ze\|FWSXCxcITvd4l{KEG\|c3H5	M{Lre\|AuOS54IN88US=>	MUKyOEBp		MofQbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	MnrSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OUOyPVAoRjJ3OEmzNlkxRC:jPh?=
MWCL-1	NITYbYpCeG:ydH;zbZMhSXO\|YYm=	MUKwMVEvPiEQvF2=	NFfTWFAzPCCq		MlvHbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	NV7NOZVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PVMzQTBpPkK1PFk{OjlyPD;hQi=>
MM.1s	MXfBdI9xfG:\|aYOgRZN{[Xl?	NGT3NIoxNTFwNjFOwG0>	NVHHTZE1OjRiaB?=		M1ToVYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	MkfrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OUOyPVAoRjJ3OEmzNlkxRC:jPh?=
HCT116	NXz0doxsTnWwY4Tpc44hSXO\|YYm=	NVewfW5FOy9zMDFOwG0>	NF;sbVQyOsLiaNMg	NUTIepE2TE2VTx?=	NVzhW4JTcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKEyFM1KtTWkh[2:wdnXyd4lwdiCjbnSgV3FUXE1zIHTl[5Ji\GG2aX;u	MoPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MUWwNlgoRjJ3N{G1NFI5RC:jPh?=
HCT116 BAX BAK1 DKO	NXWzdoh4TnWwY4Tpc44hSXO\|YYm=	MXezM\|ExKM7:TR?=	Mo\lNVLDqGkEoB?=	MUfEUXNQ	NHXN[IFqdmS3Y3XzJIEh\G:\|ZT3k[ZBmdmSnboSgbY5kemWjc3WgbY4hVEN\|Qj3JTUBkd264ZYLzbY9vKGGwZDDTVXNVVTFiZHXndoFl[XSrb36=	MmfvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MUWwNlgoRjJ3N{G1NFI5RC:jPh?=
HCT116	MmLqSpVv[3Srb36gRZN{[Xl?	Mn3GNVAh\|ryP	NHTxeZAyOsLiaNMg	M4DmTmROW09?	MmrCbY5kemWjc3XzJGdHWC2OQ{PCJJB2dmO2YR?=	NIPmeFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUexOVAzQCd-MkW3NVUxOjh:L3G+
HCT116 BAX BAK1 DKO	NHPLXpNHfW6ldHnvckBCe3OjeR?=	MnHGNVAh\|ryP	M{XsfFEzyqCqwrC=	M13ROGROW09?	Mmq4bY5kemWjc3XzJGdHWC2OQ{PCJJB2dmO2YR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdzNUCyPEc,OjV5MUWwNlg9N2F-
HCT116	NHfTSZlCfXSxcHjh[5khSXO\|YYm=	NHfJN4oyOCEQvF2=	MlXkNVLDqGkEoB?=	M3XVUmROW09?	NFfmTJlqdmS3Y3XzJIEh[2:vcHzleIUh[XW2b4DoZYdq[yC{ZYPwc45{\Q>?	NEHIO2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUexOVAzQCd-MkW3NVUxOjh:L3G+
HCT116 BAX BAK1 DKO	NXLzdoY4SXW2b4DoZYd6KEG\|c3H5	MlrRNVAh\|ryP	MmXXNVLDqGkEoB?=	NUDnbIlNTE2VTx?=	M1rWRYlv\HWlZYOgZUBkd22ybHX0[UBifXSxcHjh[4lkKHKnc4DvcpNm	NGTJdY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUexOVAzQCd-MkW3NVUxOjh:L3G+
U937	NXW1fnRxSXCxcITvd4l{KEG\|c3H5	NXrOOo11OC5zMkWtNkDPxE1?	MVuyOEBp		NUPl[odT\W6qYX7j[ZMhTEiDL2itNVEucW6mdXPl[EBieG:ydH;zbZM>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdzNECyOEc,OjV5MUSwNlQ9N2F-
U937	M1:xO2Fxd3C2b4Ppd{BCe3OjeR?=	NHP6XYExNjVizszN	NFLsU2YzPCCq		NWfxN3BQ\W6qYX7j[ZMh[2ynYY\h[4Uhd2ZiUFHSVEBidmRiY3HzdIF{\S1\|IHHzJJdmdGxiYYOgUo95[SCuZY\lcC=>	MmXrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MUSwNlQoRjJ3N{G0NFI1RC:jPh?=
HL-60 AAA-Bcl-2	NIPFeoZCeG:ydH;zbZMhSXO\|YYm=	MnG0NE02KM7:TR?=	MmXpOFghcA>?		Mo\0TWM2OD1yLki3JO69de,:jHnu[JVk\XNiY3XscEBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdzMUS2NEc,OjV5MUG0OlA9N2F-
HL-60 EEE-Bcl-2	NELPcFdCeG:ydH;zbZMhSXO\|YYm=	M2X0SFAuPSEQvF2=	NW\Ob5d1PDhiaB?=		NVvvd4U{UUN3ME21JO69de,:jDDpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NYrLO3poRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NVE1PjBpPkK1O\|EyPDZyPD;hQi=>
U87	Mkj2SpVv[3Srb36gRZN{[Xl?	MWi1NEDPxE1?	NYnRXXJYOjRiaB?=		MUfy[YR2[2W\|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy\|IH;mJG1OWC1{LDDNUXAuOTRiYX7kJGJkdC1{	NYrwOJBqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2Olc3PjNpPkK1OlY4PjZ\|PD;hQi=>
K562	MkDWR4VtdCCYaXHibYxqfHliQYPzZZk>	M2DFc\|EuOTBizszN	NX\jbVNjPDhiaB?=	MVjEUXNQ	M2jz[mlEPTB;Mk[uO{DPxE1?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7NkW2NUc,OjV3OU[1OlE9N2F-
K562/Mcl -1-IRESBim	NVHi[WlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTlwMzFOwG0>	M2SwdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUO1PVAxLz5{NUWzOVkxODxxYU6=
K562/Bcl- 2-IRESBim	M3Picmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3nHcmlEPTB;MD6zOUDPxE1?	NImwWmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWzOVkxOCd-MkW1N\|U6ODB:L3G+
Jurkat	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3K4V2lEPTB;MD62OkDPxE1?	MmrzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{W5NFAoRjJ3NUO1PVAxRC:jPh?=
JurkatΔBak	MnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoCzTWM2OD53MDFOwG0>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV\|NUmwNEc,OjV3M{W5NFA9N2F-
HL60/VCR	NHrDUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX:yR29UUUN3ME6xNFAh\|ryP	NHrN[pU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWzOVkxOCd-MkW1N\|U6ODB:L3G+
Kasumi-1	NF7yN4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTBwMEGg{txO	Mlr4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{W5NFAoRjJ3NUO1PVAxRC:jPh?=
Kasumi-1/ABT	NICwRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzOcVBCUUN3ME2wMlUyKM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV\|NUmwNEc,OjV3M{W5NFA9N2F-
THP-1	M4fCVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrITWM2OD1zLkK3JO69VQ>?	M1PKO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUO1PVAxLz5{NUWzOVkxODxxYU6=
U937	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PlRmlEPTB;NT6yPUDPxE1?	MnXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{W5NFAoRjJ3NUO1PVAxRC:jPh?=
C1498	M{LWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1z5VWlEPTB;Nj6xN{DPxE1?	NXjkeGt3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N\|U6ODBpPkK1OVM2QTByPD;hQi=>
RPMI 8226	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;lbWlEPTB;MD6yOUDPxE1?	M4TEVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUO1PVAxLz5{NUWzOVkxODxxYU6=
MM.1S	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mly0TWM2OD1yLkSwJO69VQ>?	NYXHUXVSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N\|U6ODBpPkK1OVM2QTByPD;hQi=>
NCI-H929	M2jLXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTF3LkKxJO69VQ>?	MmnTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{W5NFAoRjJ3NUO1PVAxRC:jPh?=
U266	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTBwNkig{txO	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV\|NUmwNEc,OjV3M{W5NFA9N2F-
MCF-7	NV7FTYVSS2WubDDWbYFjcWyrdImgRZN{[Xl?	NILF[pQ2KM7:TR?=	NILYfJc1QCCq	MlH1SG1UVw>?	MV\lcohidmOnczD0bIUhe2Wwc3n0bZZqfHlidH:gc5IhemGmaXH0bY9v	MmXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MEmxNlQoRjJ3NEC5NVI1RC:jPh?=
MCF-7	MkDURZBweHSxc3nzJGF{e2G7	NYezRXRYPSEQvF2=	M4r0RVQwOjRxNEigbC=>	NIHZVJNFVVOR	NYi3clE5cW6lcnXhd4V{KHSqZTDjcIVifmWmIGDBVnA>	MkewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MEmxNlQoRjJ3NEC5NVI1RC:jPh?=
MCF-7	NH;xXpRHfW6ldHnvckBCe3OjeR?=	NFTudWU2KM7:TR?=	M4fafVI1KGh?	MXPEUXNQ	MXXlcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO\|aX;uxsA>	NGG4N3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSwPVEzPCd-MkW0NFkyOjR:L3G+
MDA-MB 231	Mn;NSpVv[3Srb36gRZN{[Xl?	MUG1JO69VQ>?	NVnZVmlLOjRiaB?=	NX\YelJmTE2VTx?=	MYflcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO\|aX;uxsA>	MoLOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MEmxNlQoRjJ3NEC5NVI1RC:jPh?=
ZR-75-1	MXXGeY5kfGmxbjDBd5NigQ>?	M2f1e\|Uh\|ryP	NEC0[2szPCCq	NWTpWIllTE2VTx?=	M1ThWoVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>?	NXrIOGFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NFkyOjRpPkK1OFA6OTJ2PD;hQi=>
A549	MlvOR4VtdCCYaXHibYxqfHliQYPzZZk>	MWWwMVIxKM7:TR?=	M3TDV\|czKGh?	NH;Wc\|hFVVOR	NVLhdWx3\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?=	NVvHbW45RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPFg4PjJpPkK1N\|g5PzZ{PD;hQi=>
H1299	MU\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NVuxW\|NHOC1{MDFOwG0>	NVjiXoYzPzJiaB?=	NWrPNXJNTE2VTx?=	Mlr5[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN6OEe2Nkc,OjV\|OEi3OlI9N2F-
HO-8910	NYW1bFZsS2WubDDWbYFjcWyrdImgRZN{[Xl?	MmLENE0zOCEQvF2=	NXi2WmxkPzJiaB?=	MWLEUXNQ	MWnk[YNz\WG\|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv	NY[0fVdIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPFg4PjJpPkK1N\|g5PzZ{PD;hQi=>
HT-29	MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MmHnNE0zOCEQvF2=	NGDNdXM4OiCq	M4TE[mROW09?	MXrk[YNz\WG\|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv	NIm3XHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO4PFc3Oid-MkWzPFg4PjJ:L3G+
HCT-116	M4S5UGNmdGxiVnnhZoltcXS7IFHzd4F6	MUKwMVIxKM7:TR?=	NY\ObJI4PzJiaB?=	MXvEUXNQ	MV7k[YNz\WG\|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv	NW\rWIRnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPFg4PjJpPkK1N\|g5PzZ{PD;hQi=>
A549	MlHoRZBweHSxc3nzJGF{e2G7	M3\KcVIxKM7:TR?=	MVy0PEBp	MkLQSG1UVw>?	MV3pcoR2[2W\|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigZZNxcXKrbh?=	M2Owd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{i4O\|YzLz5{NUO4PFc3OjxxYU6=
H1299	M{fZb2Fxd3C2b4Ppd{BCe3OjeR?=	MmPENlAh\|ryP	MnPTOFghcA>?	NHX1VHNFVVOR	NILHbmxqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIgh[XOyaYLpci=>	MkXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|OEi3OlIoRjJ3M{i4O\|YzRC:jPh?=
Sc-1	MW\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MmqzNE4xODBzLUGg{txO	MYS5OkBp		MYnk[YNz\WG\|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NXXobW9WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzO\|M2ODhpPkK1N\|c{PTB6PD;hQi=>
OcI-LY18	NVT1WW1DS2WubDDWbYFjcWyrdImgRZN{[Xl?	MkD6NE4xODBzLUGg{txO	NGHRfHc6PiCq		NHz2b\|hl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M1TjOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{ezOVA5Lz5{NUO3N\|UxQDxxYU6=
RL	NVTPZ\|hPS2WubDDWbYFjcWyrdImgRZN{[Xl?	M3TuXFAvODByMT2xJO69VQ>?	NFvjWII6PiCq		NVLkUZJ{\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M1vZS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{ezOVA5Lz5{NUO3N\|UxQDxxYU6=
RKO	M{HoWmNmdGxiVnnhZoltcXS7IFHzd4F6	MViwMVExKM7:TR?=	MmTFNlTjiImqwrC=	MXLEUXNQ	NV\vdI5oUUN3ME9ihKkzPeLCidM1US=>	MlLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MESzPFMoRjJ3M{C0N\|g{RC:jPh?=
Caco-2	NWX2WJBjS2WubDDWbYFjcWyrdImgRZN{[Xl?	MUewMVExKM7:TR?=	MXiyOQKBkWkEoB?=	NFzkNVZFVVOR	MXrJR\|UxRTF7LkhihKnDvU1?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyNEO4N{c,OjV\|MESzPFM9N2F-
DLD1	MmPOR4VtdCCYaXHibYxqfHliQYPzZZk>	NFHqT5ExNTFyIN88US=>	NILpfWEzPOLCiXlCpC=>	NYe1OGlNTE2VTx?=	NUDqd\|N1UUN3ME2xPE44QOLCidM1US=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyNEO4N{c,OjV\|MESzPFM9N2F-
LS411N	NYTUSVFWS2WubDDWbYFjcWyrdImgRZN{[Xl?	M2q1VFAuOTBizszN	NVvMOW5UOjUkgJnoxsA>	M1jGS2ROW09?	MlO2TWM2OD1zMT60O-KBkcL3TR?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyNEO4N{c,OjV\|MESzPFM9N2F-
SW620	MYnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NHLwVmMxNTFyIN88US=>	NHLMdFkzPOLCiXlCpC=>	M331[mROW09?	NVLod5MyUUN3ME2xNk4zPOLCidM1US=>	Ml\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MESzPFMoRjJ3M{C0N\|g{RC:jPh?=
HCT116	NHTnXFNE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	Mo\ENE0yOCEQvF2=	NIDVS\|AzPOLCiXlCpC=>	MoHKSG1UVw>?	Mn7JTWM2OD1{MD60PgKBkcL3TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyNEO4N{c,OjV\|MESzPFM9N2F-
HaCaT	M4rBdWNmdGxiVnnhZoltcXS7IFHzd4F6	NUOzXIVbOC5zL{GvNVAh\|ryP	MlLCNlQhcA>?	NGSxcmFFVVOR	NIT4WnRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NFHtXWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKxNFc6PSd-MkWyNVA4QTV:L3G+
A5-RT3	M3zrbWNmdGxiVnnhZoltcXS7IFHzd4F6	MVGwMlEwOS9zMDFOwG0>	NVvCOlFxOjRiaB?=	NXjuS3F7TE2VTx?=	MWHk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M1Hi[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkGwO\|k2Lz5{NUKxNFc6PTxxYU6=
HaCaT	MV;GeY5kfGmxbjDBd5NigQ>?	M{LzSFEx6oDLzszN	NUX3XGJ4OjRxNEigbC=>	MXrEUXNQ	NF65R5VqdmS3Y3XzJG1OWCCjbnSgSG5CKG[{YXft[Y51[XSrb36=	NYjNV4hbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNVA4QTVpPkK1NlExPzl3PD;hQi=>
A5-RT3	MmK1SpVv[3Srb36gRZN{[Xl?	NYnEeo9POTEkgJpOwG0>	MnnWNlQwPDhiaB?=	NIfLTlJFVVOR	M4ey[olv\HWlZYOgUW1RKGGwZDDEUmEh\nKjZ33lcpRifGmxbh?=	M1juT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkGwO\|k2Lz5{NUKxNFc6PTxxYU6=
A5-RT3	MmjISpVv[3Srb36gRZN{[Xl?	MUS1JO69VQ>?	MXO2JIg>	NHS4N5BFVVOR	NVy4cHNCcW6mdXPld{B1cGVicnXs[YF{\SCxZjDtbZRw[2ixbnTybYFtKHC{b4TlbY5{KGGwZDDy[YR2[2W\|IHPsc45w\2WwaXOgd5Vzfmm4YXygbY4h[SClYYPwZZNmNWmwZHXw[Y5l\W62IH3hco5meg>?	MnLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MUC3PVUoRjJ3MkGwO\|k2RC:jPh?=
U266	MVrGeY5kfGmxbjDBd5NigQ>?	Mk\TOVAxNzd3MDDuUS=>	NWPmN2d1OjRxNEigbC=>	NUn4NJlJTE2VTx?=	MUDkc5dvemWpdXzheIV{KEKrbTygdJJqdmOrcHHscJkhfGinIFXMJIl{d2[xcn2=	NF;o[lE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKwPFg5QCd-MkWyNFg5QDh:L3G+
RPMI8226	NE\RTpZHfW6ldHnvckBCe3OjeR?=	MlfuOVAxNzd3MDDuUS=>	NGm1XJIzPC92ODDo	Mki5SG1UVw>?	MnO2[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt	M{SyclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkC4PFg5Lz5{NUKwPFg5QDxxYU6=
MM.1S	MVPGeY5kfGmxbjDBd5NigQ>?	NEPQN\|c2ODBxN{WwJI5O	NF7l[pczPC92ODDo	MkHnSG1UVw>?	MWTkc5dvemWpdXzheIV{KEKrbTygdJJqdmOrcHHscJkhfGinIFXMJIl{d2[xcn2=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJyOEi4PEc,OjV{MEi4PFg9N2F-
Clone A	NYnTS4Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjhNE4z6oDVNkCg{txO	MXm3NkBp	M2PP[mROW09?	NIr5OWVKSzVyPUeuOUDPxE1?	M2PyRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkC4PFgzLz5{NUKwPFg5OjxxYU6=
CX-1	NGXPcWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVSwMlLjiJN4MDFOwG0>	M2[xfVczKGh?	M4jidGROW09?	MWHJR\|UxRTFwODFOwG0>	M2e2ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkC4PFgzLz5{NUKwPFg5OjxxYU6=
LS174T	NHLBVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWqwMlLjiJN4MDFOwG0>	MW[3NkBp	Ml:ySG1UVw>?	NXX2ZVBsUUN3ME2xPE4{KM7:TR?=	M3\M[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkC4PFgzLz5{NUKwPFg5OjxxYU6=
HT29	MlSwRZBweHSxc3nzJGF{e2G7	M2ewb\|EwPS9zMDFOwG0>	MWC0PEBp		M3HsO4NifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M{\KbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUmyNVg5Lz5{NUG5NlE5QDxxYU6=
SW480	NIHaTJBCeG:ydH;zbZMhSXO\|YYm=	M2jKUVEwPS9zMDFOwG0>	MUW0PEBp		NVnoRng5[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MnXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzOUKxPFgoRjJ3MUmyNVg5RC:jPh?=
Colo205	NGDTfFZCeG:ydH;zbZMhSXO\|YYm=	Mnf4NU82NzFyIN88US=>	NGXwOIU1QCCq		NEfoZmdk[XW\|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NXvYepNxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxPVIyQDhpPkK1NVkzOTh6PD;hQi=>
Caco2	NWnoTFhuSXCxcITvd4l{KEG\|c3H5	NV\hSHFyOS93L{GwJO69VQ>?	M2\wW\|Q5KGh?		M4X4NoNifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF7MkG4PEc,OjVzOUKxPFg9N2F-
PCI-13	Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoTlO\|IhcA>?	NVfiUm9CTE2VTx?=	NEfvPVdIUTVyPUG1JOKyKDFwODFOwG0>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF\|OUO4O{c,OjVzM{mzPFc9N2F-
PCI-15B	NX3CUXJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mmn5O\|IhcA>?	NFzFVGpFVVOR	MYnHTVUxRTFzINMxJFQvPSEQvF2=	M1vzW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUO5N\|g4Lz5{NUGzPVM5PzxxYU6=
UM-SCC22B	NFvwd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MojEO\|IhcA>?	NVS5TVFNTE2VTx?=	NYLZSWZIT0l3ME2xPUDDuSB{Lkmg{txO	NUjuZYhERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxN\|k{QDdpPkK1NVM6Ozh5PD;hQi=>
UM-SCC47	NVyxNXBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYTpPIpbPzJiaB?=	Mnm5SG1UVw>?	MWfHTVUxRTF7INMxJFEzNjNizszN	M3SzNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUO5N\|g4Lz5{NUGzPVM5PzxxYU6=
93-VU-147T	MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXe4[WFFPzJiaB?=	M4DSPGROW09?	NYTjVmljT0l3ME20MlMhyrFiMz61JO69VQ>?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF\|OUO4O{c,OjVzM{mzPFc9N2F-
UD-SCC2	NXnHS3hpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVK3NkBp	MlXVSG1UVw>?	M4Tm[mdKPTB;MkigxtEhOi57IN88US=>	NYfqWWpYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxN\|k{QDdpPkK1NVM6Ozh5PD;hQi=>
UPCI:SCC90	M3rjRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVTYZYNXPzJiaB?=	MofuSG1UVw>?	MWXHTVUxRTZwNjFCtUAyNjVizszN	NXviT\|N2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxN\|k{QDdpPkK1NVM6Ozh5PD;hQi=>
RPMI-8226	NIf0RYNE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NVz1TYJSOTJ3L{K1NE82ODBibl2=	MV[0PIjDqA>?	M1LNS2ROW09?	NXXpTlJD\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOEKwNkc,OjVyMEiyNFI9N2F-
OPM-2	NGnGWI5E\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NHPKPVkyOjVxMkWwM\|UxOCCwTR?=	M3PjS\|Q5cMLi	MWfEUXNQ	NWH0[HFt\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NYLlbIVvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFgzODJpPkK1NFA5OjB{PD;hQi=>
RPMI-8226	Mn;tRZBweHSxc3nzJGF{e2G7	M4DTUVEzPS9{NUCvOVAxKG6P	NXjt[FU3PDiqwrC=	NYnBb5duTE2VTx?=	NHj0WlFqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NIXVRlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPFIxOid-MkWwNFgzODJ:L3G+
OPM-2	MkeyRZBweHSxc3nzJGF{e2G7	MoLnNVI2NzJ3MD:1NFAhdk1?	NEHSfnU1QGkEoB?=	M4TBeGROW09?	Mn;ObY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOEKwNkc,OjVyMEiyNFI9N2F-
COG-LL-319	M4ftSmZ2dmO2aX;uJGF{e2G7	MU[xNFAhdk1?	M3rKSFEwOy94IHi=	MV;EUXNQ	M4ntWolv\HWlZYOgZ4F{eGG\|ZT3k[ZBmdmSnboSgUYNtNTFiY3zlZZZi\2V?	NYfES3RuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OVE1PzJpPkK0PVUyPDd{PD;hQi=>
RS4;11	NYHBSnh7TnWwY4Tpc44hSXO\|YYm=	NWrsUoZEOTByIH7N	MYixM\|MwPiCq	NGWw[JBFVVOR	MlzzbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDNZ4wuOSClbHXheoFo\Q>?	NEjQR4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1NVQ4Oid-MkS5OVE1PzJ:L3G+
FL5.12	MnTtSpVv[3Srb36gZZN{[Xl?				M33QbHJmfmW{c3HsJI9nKGO7dH;rbY5mKHerdHjkdoF4[WxicILveIVkfGmxbjDpckBKVDNiZHXw[Y5l\W62IFLjcFIhd3[ncnX4dJJme3OrbnegcY92e2ViRly1MlEzKGOnbHzzJIlvKHC{ZYPlcoNmKG:oIHLveolv\SCpZXzheIlvNCCHQ{WwJF0hOC5yMEig{txONg>?	NEjGfWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K1Olg{PCd-MUeyOVY5OzR:L3G+
DoHH2	NEDxb45Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=				Mn[5TY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDpckBpfW2jbjDEc2hJOiClZXzsd{BwfmW{ZYjwdoV{e2mwZzDCZ4wzKGmwIIDy[ZNmdmOnIH;mJFMmKE[EUzygSWM2OCB;IECuNFA5OyEQvF2u	M1jlWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MkW2PFM1Lz5zN{K1Olg{PDxxYU6=
RS11380	NFjVeppIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NInrTYNKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIlvKGi3bXHuJHJUOTF\|OECgZ4VtdHNib4\ldoV5eHKnc4PpcochSmOuMjDpckBxemW\|ZX7j[UBw\iB\|JTDGRnMtKEWFNUCgQUAxNjBzNDFOwG0v	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzJ3NkizOEc,OTd{NU[4N\|Q9N2F-
FL5.12	NWDze2Z3TnWwY4Tpc44h[XO\|YYm=				M4XofHJmfmW{c3HsJI9nKGO7dH;rbY5mKHerdHjkdoF4[WxicILveIVkfGmxbjDpckBKVDNiZHXw[Y5l\W62IFLjcE15VCCxdnXy[ZhxemW\|c3nu[{Bud3W\|ZTDGUFUvOTJiY3XscJMhcW5icILld4Vv[2Vib3[gZo93cW6nIHflcIF1cW5uIFXDOVAhRSByLkCzJO69VS5?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzJ3NkizOEc,OTd{NU[4N\|Q9N2F-
FL5.12	NEPhb5dHfW6ldHnvckBie3OjeR?=				Mly2VoV3\XK\|YXygc4Yh[3m2b3vpcoUhf2m2aHTyZZdidCCycn;0[YN1cW:wIHnuJGlNOyCmZYDlcoRmdnRiQnPsNkBwfmW{ZYjwdoV{e2mwZzDtc5V{\SCITEWuNVIh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiMzWgSmJUNCCHQ{WwJF0hOC5yNTFOwG0v	NF\Ecmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K1Olg{PCd-MUeyOVY5OzR:L3G+
DoHH2	Mk\XS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				M17LVWlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigbY4hcHWvYX6gSI9JUDJiY3XscJMhd3[ncnX4dJJme3OrbnegRoNtOiCrbjDwdoV{\W6lZTDv[kAyOCViSGOsJGVEPTBiPTCwMlE{KM7:TT6=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzJ3NkizOEc,OTd{NU[4N\|Q9N2F-
RS11380	NHTEcFFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MlLFTY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDpckBpfW2jbjDSV\|EyOzhyIHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGJkdDJiaX6gdJJme2WwY3Wgc4YhOTBnIFjTMEBGSzVyIE2gNE4yPSEQvF2u	NIrUTJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K1Olg{PCd-MUeyOVY5OzR:L3G+
SUDHL4	NH;TbJJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NUOwPZBxUW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBqdiCqdX3hckBUXUSKTESgZ4VtdHNib4\ldoV5eHKnc4PpcochSmOuMjDpckBxemW\|ZX7j[UBw\iB\|JTDGRnMtKEWFNUCgQUAxNjJ{IN88UU4>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzJ3NkizOEc,OTd{NU[4N\|Q9N2F-
FL5.12	M2O2[GZ2dmO2aX;uJIF{e2G7				MYjS[ZZmenOjbDDv[kBkgXSxa3nu[UB4cXSqZILhe4FtKHC{b4TlZ5Rqd25iaX6gTWw{KGSncHXu[IVvfCCEY3ytfGwhd3[ncnX4dJJme3OrbnegcY92e2ViRly1MlEzKGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEOlJGZDWyxiRVO1NEA:KDBwMkKg{txONg>?	NXP5UoVVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUeyOVY5OzRpPkG3NlU3QDN2PD;hQi=>
SUDHL4	MmrkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				M1n5c2lvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigbY4hcHWvYX6gV3VFUEx2IHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGJkdDJiaX6gdJJme2WwY3Wgc4YhOTBnIFjTMEBGSzVyIE2gNE45PSEQvF2u	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzJ3NkizOEc,OTd{NU[4N\|Q9N2F-
FL5.12	NV;z[YlIS3m2b4TvfIlkcXS7IHHzd4F6		NW[1eJIzOjRiaILz		MkHRR5l1d3SxeHnjbZR6KGGpYXnud5QhUUx\|LXTldIVv\GWwdDDtc5V{\SCITEWuNVIh[2WubIOgc5ZmemW6cILld5NqdmdiaIXtZY4hSmOuMjDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB{NDDodpMh[nliTWTTJIF{e2G7IHnuJIFje2WwY3Wgc4Yhe2W{dX2sJGVEPTBiPTCwMlAxPzdizszNMi=>	Ml\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6NEG4PFIoRjF6OESxPFgzRC:jPh?=
FL5.12	NVqyPFZJS3m2b4TvfIlkcXS7IHHzd4F6		M2\4fFI1KGi{cx?=		M3vSV2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KEmOMz3k[ZBmdmSnboSgcY92e2ViRly1MlEzKGOnbHzzJI93\XKneIDy[ZN{cW6pIHj1cYFvKEKlbD3YUEBie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjCyOEBpenNiYomgUXRUKGG\|c3H5JIlvKGGkc3XuZ4Uhd2Zic3XyeY0tKEWFNUCgQUAxNjB\|IN88UU4>	NVyxbGVMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi4OFE5QDJpPkG4PFQyQDh{PD;hQi=>
NCI-H146	MnfRR5l1d3SxeHnjbZR6KGG\|c3H5		M1rYUFQ5KGi{cx?=		MkPpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzNE[gZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIlvKHC{ZYPlcoNmKG:oIEGwKUBpfW2jbjDz[ZJ2dSxiRVO1NEA:KDBwMEi3JO69VS5?	MkT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6NEG4PFIoRjF6OESxPFgzRC:jPh?=
CLL	NE[xWG1CeG:ydH;zbZMh[XO\|YYm=				NEfOV4hKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFPMUEBk\WyuczygSWM2OCB;IECuNFA1PSEQvF2u	NVLpV2g{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC5NlU1OzNpPkKwPVI2PDN\|PD;hQi=>
MEF	MmDCR5l1d3SxeHnjbZR6KGG\|c3H5		NEfwfFAzPCCqcoO=		NVXCc2x[S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhdWOuLUGg[IVncWOrZX70JG1GTiClZXzsd{Bi\nSncjCyOEBpenNiYomgR4VtdCC2aYTldkBodG9iYYPzZZkhcW5icILld4Vv[2Vib3[gNUUhe2W{dX2sJGVEPTBiPTCwMlAxOjB\|IN88UU4>	NXTKZWZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzOlYzQTVpPkKxN\|Y3Ojl3PD;hQi=>
MEF	M3P3TWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NXPYZ\|BvOjRiaILz		NX;SS2d[S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhdWOuLUGg[IVncWOrZX70JG1GTiClZXzsd{Bi\nSncjCyOEBpenNiYomgR4VtdCC2aYTldkBodG9iYYPzZZkhcW5icILld4Vv[2Vib3[gNVAmKHOncoXtMEBGSzVyIE2gNE4xPTFizszNMi=>	NEDrNJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO2OlI6PSd-MkGzOlYzQTV:L3G+
MEF	Ml7rR5l1d3SxeHnjbZR6KGG\|c3H5		MnnQNlQhcHK\|		MorhR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgcYNtNTFiZHXmbYNq\W62IF3FSkBk\WyuczDh[pRmeiB{NDDodpMh[nliQ3XscEB1cXSncjDncI8h[XO\|YYmgbY4heHKnc3XuZ4Uhd2ZiMUClJIZmfGGuIHLveolv\SC\|ZYL1cUwhTUN3MDC9JFAvODVzIN88UU4>	NVXofHZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzOlYzQTVpPkKxN\|Y3Ojl3PD;hQi=>
RS4:11	NVf4dG5QSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=				M1zV[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmO0PlEyKGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEGwKUBpfW2jbjDz[ZJ2dSxiRVO1NEA:KDBwMEK0JO69VS5?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl{NkK0O{c,Ojh7Mk[yOFc9N2F-
MOLT4	MXHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				Mn7URY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPT1zUOEBk\WyuczDpckBxemW\|ZX7j[UBw\iBzMDWgbJVu[W5ic3XyeY0tKEWFNUCgQUAxNjZ{MjFOwG0v	NF3vWXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEmyOlI1Pyd-Mki5NlYzPDd:L3G+
Jurkat	NFT5TGNEgXSxdH;4bYNqfHliYYPzZZk>		MXK0PEBpenN?		M2K1N2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGp2emujdDDj[YxteyCjZoTldkA1QCCqcoOgZpkh[2WubDD0bZRmei2kbIXlJIF{e2G7LDDJR\|UxKD1iMT6zPEDPxE1w	NWj6Npk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFM5PThpPkG5O\|Q{QDV6PD;hQi=>
HCT116	MWDDfZRwfG:6aXPpeJkh[XO\|YYm=		MW[0PEBpenN?		MV\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JINmdGxidHn0[ZIu[my3ZTDhd5NigSxiSVO1NEA:KDRwME[g{txONg>?	NWezcIc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFM5PThpPkG5O\|Q{QDV6PD;hQi=>
SU-8686	NX7xcYk6S3m2b4TvfIlkcXS7IHHzd4F6		M4PmTlQ5KGi{cx?=		Ml;DR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV3UuQDZ6NjDj[YxteyCjZoTldkA1QCCqcoOgZpkh[2WubDD0bZRmei2kbIXlJIF{e2G7LDDJR\|UxKD1iND6yOEDPxE1w	MkTkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NEO4OVgoRjF7N{SzPFU5RC:jPh?=
H460	MV;DfZRwfG:6aXPpeJkh[XO\|YYm=		MVS0PEBpenN?		NF7UboVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJPDZyIHPlcIx{KGGodHXyJFQ5KGi{czDifUBk\WyuIITpeIVzNWKudXWgZZN{[XluIFnDOVAhRSB6LkCzJO69VS5?	M{HHOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{SzPFU5Lz5zOUe0N\|g2QDxxYU6=
Hepa-1c1c7	M{LWe2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MmjzOFghcHK\|		NFzxOoJEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBJ\XCjLUHjNYM4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDj[YxtKHSrdHXyMYJtfWViYYPzZZktKEmFNUCgQUA5NjZ6IN88UU4>	Mo\uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NEO4OVgoRjF7N{SzPFU5RC:jPh?=
MCF7	NUH2d41TS3m2b4TvfIlkcXS7IHHzd4F6		MVu0PEBpenN?		MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDj[YxtKHSrdHXyMYJtfWViYYPzZZktKEmFNUCgQUAzOS5{NjFOwG0v	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd2M{i1PEc,OTl5NEO4OVg9N2F-
DU145	NWLjboJJS3m2b4TvfIlkcXS7IHHzd4F6		M3O5S\|Q5KGi{cx?=		NH[5[IlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCjZoTldkA1QCCqcoOgZpkh[2WubDD0bZRmei2kbIXlJIF{e2G7LDDJR\|UxKD1iMkeuOkDPxE1w	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd2M{i1PEc,OTl5NEO4OVg9N2F-
HCT116	MVzDfZRwfG:6aXPpeJkh[XO\|YYm=		NYfDR3BzPzJiaILz		NFH0NYhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiZYjwdoV{e2mwZzDCZ4wugExuIFLjcE0zKGGwZDDNZ4wuOSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hPDdwNzFOwG0v	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF5MkewNUc,OjJzN{K3NFE9N2F-
BL21 (DE3)	MWLGeY5kfGmxbjDhd5NigQ>?		NUHlZ3pVOiCqcoO=		MonRRolv\GmwZzDh[oZqdmm2eTD0c{BPNXSncn3pcpV{KD[[IFjpd{11[WepZXSgbJVu[W5iQnPsNkBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJEhFTTNrIHPlcIx{KGGodHXyJFIhcHK\|IHL5JIZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZZN{[XluIFnDOVAhRSByLkCwNkDPxE1w	NHLBPVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS0PFk5QCd-MkK0OFg6QDh:L3G+
BL21 (DE3)	Ml\DSpVv[3Srb36gZZN{[Xl?		MXSyJIhzew>?		M3LwS2JqdmSrbnegZYZncW6rdImgeI8hVi22ZYLtbY52eyB6WDDIbZMufGGpZ3XkJIh2dWGwIFLjcE15VCCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKCiGRUOpJINmdGy\|IHHmeIVzKDJiaILzJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[XO\|YYmsJGlEPTBiPTCwMlAxPiEQvF2u	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR2OEm4PEc,OjJ2NEi5PFg9N2F-
NCI-H146	NWrV[IZ1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVO0JIRigXN?		NHPmV\|ZIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG0OkBk\WyuczDh[pRmeiB2IHThfZMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuNFk4KM7:TT6=	M124WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NES4PVg5Lz5{MkS0PFk5QDxxYU6=
NCI-H1417	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4\PPVQh\GG7cx?=		MWTHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDF2MUegZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KFeVVEigZZN{[XluIFnDOVAhRSByLkGzJO69VS5?	NXXjZXo6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0OFg6QDhpPkKyOFQ5QTh6PD;hQi=>
CCRF-CEM	MX7DfZRwfG:6aXPpeJkh[XO\|YYm=		MVK0PEBpenN?		NIrDTmtEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBES1KILVPFUUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliY3XscJRqfGW{LXLseYUh[XO\|YYmsJGlEPTBiPTCwMlc1KM7:TT6=	M3iyZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUiyPVkyLz5{MkW4Nlk6OTxxYU6=
HL60	NH3ZXZVEgXSxdH;4bYNqfHliYYPzZZk>		NYGyUVZ4PDhiaILz		NHHWbo5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBk\WyudHn0[ZIu[my3ZTDhd5NigSxiSVO1NEA:KDBwN{[g{txONg>?	NHf1O4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW4Nlk6OSd-MkK1PFI6QTF:L3G+
K562	MVLDfZRwfG:6aXPpeJkh[XO\|YYm=		NYXVNXA2PDhiaILz		M1i4bGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGs2PjJiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JINmdGy2aYTldk1jdHWnIHHzd4F6NCCLQ{WwJF0hOzRwNzFOwG0v	MkPNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3OEK5PVEoRjJ{NUiyPVkyRC:jPh?=
NCI-H146	NWDFSYxESW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3;tWlQh\GG7cx?=		NX3G[4F[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDF2NjDj[YxteyCjZoTldkA1KGSjeYOgZpkhX1OWODDhd5NigSxiSVO1NEA:KDBwMEO3JO69VS5?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd2N{W5PEc,OjJ5NEe1PVg9N2F-
NCI-H1963	MoDURY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NE\NVmI1KGSjeYO=		MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3INVk3OyClZXzsd{Bi\nSncjC0JIRigXNiYomgW3NVQCCjc4PhfUwhUUN3MDC9JFAvODV7IN88UU4>	M{i0dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{S3OVk5Lz5{Mke0O\|U6QDxxYU6=
NCI-H1417	NWTBbFRvSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NVzm[3J4PCCmYYnz		MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3INVQyPyClZXzsd{Bi\nSncjC0JIRigXNiYomgW3NVQCCjc4PhfUwhUUN3MDC9JFAvPDF{IN88UU4>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd2N{W5PEc,OjJ5NEe1PVg9N2F-
RS4:11	NVm1TFJFSXCxcITvd4l{KGG\|c3H5		MXO0PEBpenN?		M4\XN2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gRoNtOiCmZYDlcoRmdnRiaIXtZY4hWlN2OkGxJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCDbn7lfIlvKFZic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2comsJGlEPTBiPTCwMlI4KM7:TT6=	NGr3Z409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxOFA2PCd-MkOzNVQxPTR:L3G+
K562	MYfBdI9xfG:\|aYOgZZN{[Xl?		NGfsUYc1QCCqcoO=		NUX5bYkxUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBO[2xzIHTldIVv\GWwdDDoeY1idiCNNU[yJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCDbn7lfIlvKFZic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2comsJGlEPTBiPTCxOk41KM7:TT6=	M{TPR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{G0NFU1Lz5{M{OxOFA2PDxxYU6=
NCI-H1963	NGLkWpFEgXSxdH;4bYNqfHliYYPzZZk>		NEH4VWU1KGSjeYO=		MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDF7NkOgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiNDDkZZl{KGK7IGfTWEBie3OjeTygTWM2OCB;IECuNFU1KM7:TT6=	M1[xXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NES4Nlk5Lz5{M{S0PFI6QDxxYU6=
NCI-H187	M3n4bWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MknMOEBl[Xm\|		MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDF6NzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2IHThfZMh[nliV2PUJIF{e2G7LDDJR\|UxKD1iMD6xN\|c4KM7:TT6=	Mmf4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2NEiyPVgoRjJ\|NES4Nlk5RC:jPh?=
NCI-H1417	MXPDfZRwfG:6aXPpeJkh[XO\|YYm=		NEjicms1KGSjeYO=		MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDF2MUegZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiNDDkZZl{KGK7IGfTWEBie3OjeTygTWM2OCB;IECuNVc{PCEQvF2u	NFPZfJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S0PFI6QCd-MkO0OFgzQTh:L3G+
HL60	Mn23S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVm3NkBpenN?		NI\wTHRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJVDZyIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjl5IN88UU4>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzdzMkmzPUc,Ojd5MUK5N\|k9N2F-
MCF7	M1;EdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWe3NkBpenN?		MmrjS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNlUvOzNizszNMi=>	MmLKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5MUK5N\|koRjJ5N{GyPVM6RC:jPh?=
U266	Mkn1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NX\X[WlHPzJiaILz		NVnOOmJ2T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hXTJ4NjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOjdwM{Wg{txONg>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzdzMkmzPUc,Ojd5MUK5N\|k9N2F-
SKOV3	NVO0e3o5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{XvbVczKGi{cx?=		NWrTZYsyT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0uRVkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDR4LkW5JO69VS5?	Mn7FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5MUK5N\|koRjJ5N{GyPVM6RC:jPh?=
RS4:11	MnLhR5l1d3SxeHnjbZR6KGG\|c3H5		MUSyOEBpenN?		NGq0OVREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBTWzR8MUGgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlM{KM7:TT6=	M1rGfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEWzNVM2Lz5{OUS1N\|E{PTxxYU6=
Remb1	MkHTR5l1d3SxeHnjbZR6KGG\|c3H5		MV2yOEBpenN?		NHfzW5ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBT\W2kMTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiMkSgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGuOEDPxE1w	NXPybHF4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OVMyOzVpPkK5OFU{OTN3PD;hQi=>
BL21	MojqSpVv[3Srb36gZZN{[Xl?	NVXOfY9VOTBidV2=	M2Da[FMhcHK\|		M3juUmRqe3CuYXPlcYVvfCCxZjDCU2RKWFlvQnHrJINwdmq3Z3H0[YQheGWydHnk[UBnem:vIFfTWE11[WepZXSgbJVu[W5iQnPsMVIudGmtZTDwdo91\WmwIEGgS\|E6PkFibYX0ZY51KGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEh[2WubIOgZZQhOTBidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiClb33w[ZRqfGmxbjDhd5NigSxiS3mgQUAxNjByMTFOwG0v	Mk[1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEe1NVIoRjJzOEC3OVEzRC:jPh?=
BL21	NEfQflNHfW6ldHnvckBie3OjeR?=	MmmwNVAhfU1?	NGTwcpI{KGi{cx?=		MWnEbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NUKjazDjc45rfWejdHXkJJBmeHSrZHWg[pJwdSCJU2SteIFo\2WmIHj1cYFvKEKlbD2yMYxqc2VicILveIVqdiBzIFG5N3YhdXW2YX70JIV5eHKnc4Pl[EBqdiCHc3Po[ZJq[2irYTDjc4xqKEKOMkGgZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhOyCqcoOgZpkh\my3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBkd22yZYTpeIlwdiCjc4PhfUwhU2liPTCwMlAxOTRizszNMi=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThyN{WxNkc,OjF6MEe1NVI9N2F-
BL21	M4PrVGZ2dmO2aX;uJIF{e2G7	NWq3emt[OTBidV2=	MWmzJIhzew>?		MV7EbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NUKjazDjc45rfWejdHXkJJBmeHSrZHWg[pJwdSCJU2SteIFo\2WmIHj1cYFvKEKlbD2yMYxqc2VicILveIVqdiBzIGmxPVVHKG23dHHueEBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJINmdGy\|IHH0JFExKHWPIHHmeIVzKDNiaILzJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[2:vcHX0bZRqd25iYYPzZZktKEurIE2gNE4xODF3IN88UU4>	NY\qdo1GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFc2OTJpPkKxPFA4PTF{PD;hQi=>
BL21	Mn2wSpVv[3Srb36gZZN{[Xl?	MoD1NVAhfU1?	NY\2dJRmOyCqcoO=		MYTEbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NUKjazDjc45rfWejdHXkJJBmeHSrZHWg[pJwdSCJU2SteIFo\2WmIHj1cYFvKFerbHSgeJlx\SCEY3ytNk1tcWunIIDyc5RmcW5iMTDlfJBz\XO\|ZXSgbY4hTXOlaHXybYNpcWFiY3;sbUBDVDJzIHPlcIx{KGG2IEGwJJVOKGGodHXyJFMhcHK\|IHL5JIZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZ49ueGW2aYTpc44h[XO\|YYmsJGtqKD1iMD6wNFM1KM7:TT6=	NFjqUWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwO\|UyOid-MkG4NFc2OTJ:L3G+
BL21	NXPScYpCTnWwY4Tpc44h[XO\|YYm=	MnO0NVAhfU1?	MXizJIhzew>?		NYWxSVdwTGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3CZYsh[2:waoXnZZRm\CCyZYD0bYRmKG[{b32gS3NVNXSjZ3fl[EBpfW2jbjDCZ4wuOi2uaXvlJJBzd3SnaX6gNUBGOTJ7SDDteZRidnRiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSClZXzsd{BifCBzMDD1UUBi\nSncjCzJIhzeyCkeTDmcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHPvcZBmfGm2aX;uJIF{e2G7LDDLbUA:KDBwMEC0OUDPxE1w	M1P2VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21	MUnGeY5kfGmxbjDhd5NigQ>?	NIrNNWoyOCC3TR?=	MUCzJIhzew>?		NG\sVHVFcXOybHHj[Y1mdnRib3[gRm9FUVC\LVLhb{Bkd26sdXfheIVlKHCncITp[IUh\nKxbTDHV3QufGGpZ3XkJIh2dWGwIFLjcE0zNWyra3WgdJJwfGWrbjCxJGU6PkdibYX0ZY51KGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEh[2WubIOgZZQhOTBidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiClb33w[ZRqfGmxbjDhd5NigSxiS3mgQUAxNjByNUig{txONg>?	M2DMc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21	NVLGR21KTnWwY4Tpc44h[XO\|YYm=	NGTRSoUyOCC3TR?=	NVu0Um1yOyCqcoO=		Mn7ZSIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2EYXugZ49vcnWpYYTl[EBx\XC2aXTlJIZzd21iR2PUMZRi\2enZDDoeY1idiCEY3ytNk1tcWunIIDyc5RmcW5iMTDBNVQzT2SnbIThNVM3XCCvdYThcpQh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUBk\WyuczDheEAyOCC3TTDh[pRmeiB\|IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGOxbYDleIl1cW:wIHHzd4F6NCCNaTC9JFAvODFizszNMi=>	M3TKN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21	NEDOfmtHfW6ldHnvckBie3OjeR?=	MXuxNEB2VQ>?	M4rYXlMhcHK\|		NX7EcFFlTGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3CZYsh[2:waoXnZZRm\CCyZYD0bYRmKG[{b32gS3NVNXSjZ3fl[EBpfW2jbjDCZ4wuOi2uaXvlJJBzd3SnaX6gNUBCOTR{RzDteZRidnRiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSClZXzsd{BifCBzMDD1UUBi\nSncjCzJIhzeyCkeTDmcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHPvcZBmfGm2aX;uJIF{e2G7LDDLbUA:KDBwMEKxJO69VS5?	NUPEVGV[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFc2OTJpPkKxPFA4PTF{PD;hQi=>
BL21	MVjGeY5kfGmxbjDhd5NigQ>?	NVnPcXM6OTBidV2=	NHvMZnU{KGi{cx?=		NFfsVm9FcXOybHHj[Y1mdnRib3[gRm9FUVC\LVLhb{Bkd26sdXfheIVlKHCncITp[IUh\nKxbTDHV3QufGGpZ3XkJIh2dWGwIFLjcE0zNWyra3WgdJJwfGWrbjCxJGwyOzCYIH31eIFvfCCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEOgbJJ{KGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iY3;tdIV1cXSrb36gZZN{[XluIFvpJF0hOC5yNUig{txONg>?	M2fpR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21	NVTFW28xTnWwY4Tpc44h[XO\|YYm=	M2SzN\|ExKHWP	MXOzJIhzew>?		NYPoUXNZTGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3CZYsh[2:waoXnZZRm\CCyZYD0bYRmKG[{b32gS3NVNXSjZ3fl[EBpfW2jbjDCZ4wuOi2uaXvlJJBzd3SnaX6gNUBl\Wy2YUGzOnQhdXW2YX70JIV5eHKnc4Pl[EBqdiCHc3Po[ZJq[2irYTDjc4xqKEKOMkGgZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhOyCqcoOgZpkh\my3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBkd22yZYTpeIlwdiCjc4PhfUwhU2liPTCwMlA3KM7:TT6=	M2TT[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEC3OVEzLz5{MUiwO\|UyOjxxYU6=
BL21	MkDTSpVv[3Srb36gZZN{[Xl?	MVuxNEB2VQ>?	M132VlMhcHK\|		Mm\KSIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2EYXugZ49vcnWpYYTl[EBx\XC2aXTlJIZzd21iR2PUMZRi\2enZDDoeY1idiCEY3ytNk1tcWunIIDyc5RmcW5iMTDMNVMxSSCvdYThcpQh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUBk\WyuczDheEAyOCC3TTDh[pRmeiB\|IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGOxbYDleIl1cW:wIHHzd4F6NCCNaTC9JFAvODd\|IN88UU4>	NXPyNZJqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFc2OTJpPkKxPFA4PTF{PD;hQi=>
BL21	MlPWSpVv[3Srb36gZZN{[Xl?	M4jjbVExKHWP	NEO0cHA{KGi{cx?=		MVrEbZNxdGGlZX3lcpQhd2ZiQl;ETXB[NUKjazDjc45rfWejdHXkJJBmeHSrZHWg[pJwdSCJU2SteIFo\2WmIHj1cYFvKEKlbD2yMYxqc2VicILveIVqdiBzIGKxNFBGKG23dHHueEBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJINmdGy\|IHH0JFExKHWPIHHmeIVzKDNiaILzJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[2:vcHX0bZRqd25iYYPzZZktKEurIE2gNE4yPiEQvF2u	NInYNFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwO\|UyOid-MkG4NFc2OTJ:L3G+
BL21	MXLGeY5kfGmxbjDhd5NigQ>?	Ml7zNVAhfU1?	M1TN[FMhcHK\|		NHHsdXhFcXOybHHj[Y1mdnRib3[gRm9FUVC\LVLhb{Bkd26sdXfheIVlKHCncITp[IUh\nKxbTDHV3QufGGpZ3XkJIh2dWGwIFLjcE0zNWyra3WgdJJwfGWrbjCxJHYyPDGDIH31eIFvfCCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEOgbJJ{KGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iY3;tdIV1cXSrb36gZZN{[XluIFvpJF0hOC5zOTFOwG0v	MnTNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEe1NVIoRjJzOEC3OVEzRC:jPh?=
BL21	Ml7ZSpVv[3Srb36gZZN{[Xl?	MVGxNEB2VQ>?	MlLiN{BpenN?		Mk\hSIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2EYXugZ49vcnWpYYTl[EBx\XC2aXTlJIZzd21iR2PUMZRi\2enZDDoeY1idiCEY3ytNk1tcWunIIDyc5RmcW5iMTDBNVQzXCCvdYThcpQh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUBk\WyuczDheEAyOCC3TTDh[pRmeiB\|IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGOxbYDleIl1cW:wIHHzd4F6NCCNaTC9JFAvOjdizszNMi=>	NYK5SJdZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFc2OTJpPkKxPFA4PTF{PD;hQi=>
BL21	M2K5dWZ2dmO2aX;uJIF{e2G7	MXyxNEB2VQ>?	NVXhfHJEOyCqcoO=		NXzaSYRyTGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3CZYsh[2:waoXnZZRm\CCyZYD0bYRmKG[{b32gS3NVNXSjZ3fl[EBpfW2jbjDCZ4wuOi2uaXvlJJBzd3SnaX6gNUBNOTNyRzDteZRidnRiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSClZXzsd{BifCBzMDD1UUBi\nSncjCzJIhzeyCkeTDmcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHPvcZBmfGm2aX;uJIF{e2G7LDDLbUA:KDBwMkmg{txONg>?	NVTlU2FDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFc2OTJpPkKxPFA4PTF{PD;hQi=>
BL21	MXTGeY5kfGmxbjDhd5NigQ>?	MkDJNVAhfU1?	NGHDWJU{KGi{cx?=		MkXrSIl{eGyjY3Xt[Y51KG:oIFLPSGlRYS2EYXugZ49vcnWpYYTl[EBx\XC2aXTlJIZzd21iR2PUMZRi\2enZDDoeY1idiCEY3ytNk1tcWunIIDyc5RmcW5iMTDGPVdXKG23dHHueEBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJINmdGy\|IHH0JFExKHWPIHHmeIVzKDNiaILzJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[2:vcHX0bZRqd25iYYPzZZktKEurIE2gNE4{KM7:TT6=	MlHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEe1NVIoRjJzOEC3OVEzRC:jPh?=
BL21	Moe3SpVv[3Srb36gZZN{[Xl?	MY[xNEB2VQ>?	M2X4eFMhcHK\|		NUSzVoNmTGm\|cHzhZ4Vu\W62IH;mJGJQTEmSWT3CZYsh[2:waoXnZZRm\CCyZYD0bYRmKG[{b32gS3NVNXSjZ3fl[EBpfW2jbjDCZ4wuOi2uaXvlJJBzd3SnaX6gNUB[OTBzSDDteZRidnRiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSClZXzsd{BifCBzMDD1UUBi\nSncjCzJIhzeyCkeTDmcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHPvcZBmfGm2aX;uJIF{e2G7LDDLbUA:KDBwM{ig{txONg>?	NELFT\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwO\|UyOid-MkG4NFc2OTJ:L3G+
BL21 (DE3)	MlWzSpVv[3Srb36gZZN{[Xl?		MonjNkBpenN?		MVnCbY5lcW6pIHHm[olvcXS7IITvJG4ufGW{bXnueZMhPlhiSHnzMZRi\2enZDDoeY1idiCEY3yyJIV5eHKnc4Pl[EBqdiCHc3Po[ZJq[2irYTDjc4xqKEKOMkGgLGRGOyliY3XscJMh[W[2ZYKgNkBpenNiYomg[ox2d3Knc3PlcoNmKHCxbHHybZpifGmxbjDhd5NigSxiS3mgQUAxNjByME[g{txONg>?	M2DCO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NES4PVg5Lz5{MkS0PFk5QDxxYU6=
BL21 (DE3)	M1fwNmZ2dmO2aX;uJIF{e2G7		MnnyNkBpenN?		NIHLbnFDcW6maX7nJIFn\mmwaYT5JJRwKE5vdHXycYlvfXNiOGigTIl{NXSjZ3fl[EBpfW2jbjDCZ4wugExiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSBqRFWzLUBk\WyuczDh[pRmeiB{IHjyd{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGG\|c3H5MEBMcSB;IECuNFAyKM7:TT6=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR2OEm4PEc,OjJ2NEi5PFg9N2F-
Toledo	M33J[mFxd3C2b4Ppd{Bie3OjeR?=				NIq2OppKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIGTvcIVldyClZXzsd{whVER3MDC9JFAvODZizszNMi=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyME[1Nkc,OjR7MEC2OVI9N2F-
KB	MWHDfZRwfG:6aXPpeJkh[XO\|YYm=	MYmwMlUhfU1?			MVzDfZRwfG:6aXPpeJkhcW5iaIXtZY4he2mUTlGtcYVlcWG2ZXStUWNNOS2tbnPvb{Bld3ewIFvCJINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKEKFTEKgZZQhOC53IIXN	M3fXT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MESwNFQ{Lz5zOEC0NFA1OzxxYU6=
Eu-Myc	M{PTS2Fxd3C2b4Ppd{Bie3OjeR?=	NF3WV\|gyKHWP			NIXSb4FKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJI1wfXOnIFX1MW16[yClZXzsd{BwfmW{ZYjwdoV{e2mwZzDCR2wzKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2:ub375JIZwem2jdHnvckBifCBzIIXN	MnXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyNECwOFMoRjF6MESwNFQ{RC:jPh?=
HeLa	MXzGeY5kfGmxbjDhd5NigQ>?	NY\EbFZbOSC3TR?=	M4P5RVEzKGi{cx?=		MXTJcoR2[3Srb36gc4YhSmOuLYjMMY1m\GmjdHXkJIFxd3C2b4Ppd{BqdiCmb4j5Z5lkdGmwLYP0bY12dGG2ZXSgbJVu[W5iSHXMZUBk\WyuczDveoVz\XiycnXzd4lv\yCQb4jhJIF1KDFidV2gZYZ1\XJiMUKgbJJ{KGK7IFjv[YNpe3Ric4ThbY5qdmd?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN6Nkm4Nkc,OjJ\|OE[5PFI9N2F-
HeLa	M3HIV2Z2dmO2aX;uJIF{e2G7	M2e3elExKHWP	MX6xOkBpenN?		NFHZS3RKdmirYnn0bY9vKG:oIGLseYMuSmG6L3XZSnAuSmOuLYjMJIlvfGW{YXP0bY9vKGW6cILld5Nm\CCrbjDoeY1idiCKZVzhJINmdGy\|IHH0JFExKHWPIHHmeIVzKDF4IHjyd{BjgSCEUlXUJIF{e2G7	M1rES\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEK1NFMyLz5{MkSyOVA{OTxxYU6=
MDA-MB-231	NUfCUmZGTnWwY4Tpc44h[XO\|YYm=	MV[wMlA{KHSxIEGgeW0>	Mmj0NUBpeg>?		NWLkTXFESW62YXfvcol{fCCjY4Tpeol1gSCjdDDy[YNwdWKrbnHueEBD[2xvWFygZZN{\XO\|ZXSgZZMhemW\|dH;yZZRqd25ib3[gRmlOKEKKMz3pcoR2[2WmIGPtZYMheHKxdHXpckBz\WynYYPlJIlvKG2rdH;jbI9v\HKrYTDpd49t[XSnZDDmdo9uKE2GQT3NRk0zOzFiY3XscJMh[XRiMD6wN{B1dyBzIIXNJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NGe3RVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke0O\|U6QCd-MkK3OFc2QTh:L3G+
MDA-MB-231	NEDWWoRHfW6ldHnvckBie3OjeR?=	M1TwSlAvODNidH:gNUB2VQ>?	NVXzUJh3OSCqch?=		MmewRY51[WexbnnzeEBi[3Srdnn0fUBifCC{ZXPvcYJqdmGwdDDCZ4wuYExiYYPz[ZN{\WRiYYOgdoV{fG:{YYTpc44hd2ZiQlnNJGJJOy2rbnT1Z4VlKGO7dH;jbJJwdWViYzDy[Yxm[XOnIHnuJI1qfG:laH;u[JJq[SCrc3;sZZRm\CCocn;tJG1FSS2PQj2yN\|Eh[2WubIOgZZQhOC5yMzD0c{AyKHWPIHHmeIVzKDFiaIKgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	NE\uNHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke0O\|U6QCd-MkK3OFc2QTh:L3G+
BP3	MWrBdI9xfG:\|aYOgZZN{[Xl?	NUnwVXFYOTBidV2=	M4nwclI1KGi{cx?=		NFn3XoxKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFLQN{Bk\WyuczDheEAyOCC3TTDpcoN2[mG2ZXSg[o9zKDJ2IHjyd{BjgSCDbn7lfIlvKFZiYX7kJJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRiRlHDV{Bu\XSqb3S=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB2N{KyPEc,OjNyNEeyNlg9N2F-
IM9	MlzTRZBweHSxc3nzJIF{e2G7	NUHPbFBpOTBidV2=	MXyyOEBpenN?		NInOfpZKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFnNPUBk\WyuczDheEAyOCC3TTDpcoN2[mG2ZXSg[o9zKDJ2IHjyd{BjgSCDbn7lfIlvKFZiYX7kJJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRiRlHDV{Bu\XSqb3S=	NFnSVXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C0O\|IzQCd-MkOwOFczOjh:L3G+
RS4:11	MYrBdI9xfG:\|aYOgZZN{[Xl?	NFmyUZgyOCC3TR?=	MWKyOEBpenN?		NFG1cnBKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIGLTOFoyOSClZXzsd{BifCBzMDD1UUBqdmO3YnH0[YQh\m:{IEK0JIhzeyCkeTDBco5mgGmwIG[gZY5lKHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoch[mG\|ZXSgSmFEWyCvZYToc4Q>	NHnPbVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C0O\|IzQCd-MkOwOFczOjh:L3G+
HCT116	MUfBdI9xfG:\|aYOgZZN{[Xl?		MnO3OFghcHK\|		NInxbWxKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFjDWFEyPiCyNUOrM{sh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IFHucoV5cW5iVj3GTXREKHO2YXnubY5oNWKjc3XkJIZtd3diY4n0c41mfHKrYzDt[ZRpd2R?	NHPBToM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm4NlM4Oid-Mk[5PFI{PzJ:L3G+
DMS53	NVPOSHB3SXCxcITvd4l{KGG\|c3H5	NEnyc5k2KHSxIEGwJJVO	MoO1NVIhcHK\|		NWL2THFCUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDEUXM2OyClZXzsd{Bp[XKkb4LpcocheDV\|IH31eIFvfCCjc4Pld5Nm\CCjczDjfZRw[2i{b33lJIMhemWuZXHz[UBifCB3IITvJFExKHWPIHHmeIVzKDF{IHjyd{BjgSCrbX31co9jdG:2dHnu[{Bu\XSqb3S=	NH7RXnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm4NlM4Oid-Mk[5PFI{PzJ:L3G+
DMS53	Ml6zSpVv[3Srb36gZZN{[Xl?	MVi1JJRwKDFyIIXN	MX6xNkBpenN?		MXHJcohq[mm2aX;uJI9nKEKFbD2yM2JqdSCrboTldoFkfGmxbjDpckBpfW2jbjDEUXM2OyClZXzsd{Bp[XKkb4LpcocheDV\|IH31eIFvfCCjdDC1JJRwKDFyIIXNJIFnfGW{IEGyJIhzeyCkeTDpcY12dm:ycnXjbZBqfGG2aX;uJI1mfGixZB?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl6MkO3Nkc,OjZ7OEKzO\|I9N2F-
DMS53	NWDIelZNSXCxcITvd4l{KGG\|c3H5	MoTNOUB1dyBzMDD1US=>	MVWxNkBpenN?		MnPvTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCGTWO1N{Bk\WyuczDoZZJjd3KrbnegdFU{KG23dHHueEBie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDVidH:gNVAhfU1iYX\0[ZIhOTJiaILzJIJ6KGmvbYXuc4Jtd3S2aX7nJI1mfGixZB?=	NXvTd4U5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5PFI{PzJpPkK2PVgzOzd{PD;hQi=>
DMS53	MoHVRZBweHSxc3nzJIF{e2G7	MlzKOUB1dyBzMDD1US=>	NHO1[ooyOiCqcoO=		NIrKd4ZKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFTNV\|U{KGOnbHzzJIhiemKxcnnu[{BxPTNibYX0ZY51KGG\|c3Xzd4VlKGG\|IHPhd5Bie2VvMzDjcIVifmGpZTDheEA2KHSxIEGwJJVOKGGodHXyJFEzKGi{czDifUBqdW23bn;icI91fGmwZzDt[ZRpd2R?	NWLFfo9YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5PFI{PzJpPkK2PVgzOzd{PD;hQi=>
DMS53	NXTUZW5HTnWwY4Tpc44h[XO\|YYm=	MVq1JJRwKDFyIIXN	MVOxNkBpenN?		NXjYb5hlUW6qaXLpeIlwdiCxZjDCR4wuOi:EYYigbY51\XKjY4Tpc44hcW5iaIXtZY4hTE2VNUOgZ4VtdHNiaHHyZo9zcW6pIIC1N{BufXSjboSgZZQhPSC2bzCxNEB2VSCjZoTldkAyOiCqcoOgZpkhcW2vdX7vdJJm[2myaYTheIlwdiCvZYToc4Q>	Mo\2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7OEKzO\|IoRjJ4OUiyN\|czRC:jPh?=
U-2 OS	MXXxTHRUKGG\|c3H5				MkSydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFVvMjDPV{Bk\Wyucx?=	NGq3RY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	MnXYdWhVWyCjc4PhfS=>				MnHndWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	M3LYRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	MWDxTHRUKGG\|c3H5				NFvyXZlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?=	M36xRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	MYfxTHRUKGG\|c3H5				NXXtc5lSeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	NYHPTYZoeUiWUzDhd5NigQ>?				MW\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	MlviQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	MXfxTHRUKGG\|c3H5				NVjkWoVueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	MoT5dWhVWyCjc4PhfS=>				M3PEZ5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO=	Mni4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	M1THVpFJXFNiYYPzZZk>				M1fjO5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	NFyxbIJyUFSVIHHzd4F6				NFTIW\|JyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBNSU5vNTDj[Yxtew>?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	NX33WpkzeUiWUzDhd5NigQ>?				MY\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDERW9[KGOnbHzz	NHrGbHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	MULxTHRUKGG\|c3H5				NYPHWmNFeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	M3y0WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	MXXxTHRUKGG\|c3H5				NYjUNZBYeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO=	MnHrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	NWLkS5FQeUiWUzDhd5NigQ>?				NWix[nJieUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl?	NV6yU4lqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30	NXPHSVlleUiWUzDhd5NigQ>?				NUPSWnFyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoN\|Ah[2WubIO=	NYTrUIRoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	MUPxTHRUKGG\|c3H5				MXXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDNS{A3OyBqNj3US{BTMSClZXzsdy=>	NUfnUmlJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS	M{nPN5FJXFNiYYPzZZk>				NIWzSYNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBWNTJiT2OgZ4VtdHN?	M4PveVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	MVHxTHRUKGG\|c3H5				MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFQyKGOnbHzz	NFrl[Go9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	NUfDOphyeUiWUzDhd5NigQ>?				M4n1c5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	NGe5Wmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	Ml3YdWhVWyCjc4PhfS=>				M4rGWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	NYP1RmJCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	NE[5ZoVyUFSVIHHzd4F6				NXT5SZAyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	M4fFcZFJXFNiYYPzZZk>				MWnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	MmrZdWhVWyCjc4PhfS=>				NX;Mb\|NpeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	M1nEO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	M1XPT5FJXFNiYYPzZZk>				NHL2bWtyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBPSjF4NEOgZ4VtdHN?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	MWjxTHRUKGG\|c3H5				Ml74dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[Yxtew>?	M3zrUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32	MWLxTHRUKGG\|c3H5				MYfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR\|MzKGOnbHzz	M{DSfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18	NFjwR4ZyUFSVIHHzd4F6				NFvtfYJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDF6IHPlcIx{	M{TtT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	MXnxTHRUKGG\|c3H5				MlzSdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV4Fwey1{IHPlcIx{	NVHwVW9KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	PARP / c-PARP / cleaved caspase 3 ; PubMed: 21393866 J Clin Invest H146 cells were preincubated in normoxia or hypoxia (1% O2) for 18 hours prior to treatment with ABT-737 (89.1 nM ), after which cells were harvested for protein analysis by Western blot. Hif-1a; PubMed: 22006676 Mol Cancer Ther Representative western blots for HIF-1α, PARP and cleaved caspase 3 in response to 24-72 hr exposure to ABT-737 in varying concentration in normoxia and hypoxia in 4 neuroblastoma cell lines. Actin is shown as a loading control. Blots are representative of 3 independent experiments. γ-H2AX / p-ATM; PubMed: 21084274 Cancer Res Induction of γ-H2AX and p-ATM by ABT-737. Cells were treated with 10 µmol/L ABT-737 for 24 hours and then maintained in fresh media for 1 or 2 more days prior to Western blot analysis.	21393866 22006676 21084274
Immunofluorescence	cytochrome C; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the release of mitochondrial cytochrome c (green) into the cytoplasm after ABT-737 exposure (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field. Bax; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the mitochondrial translocation of Bax from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field C. To assess whether ABT-737 treatment has an effect on the dimerization of Bax, the levels of dimeric Bax were measured with or without ABT-737 treatment in MC-3 and HN22 cells. Bim; PubMed: 26447615 Oncotarget Immunocytochemistry revealed the mitochondrial translocation of Bim from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field. AIF; PubMed: 25034785 Cell Death Differ localization of apoptosis inducing factor (AIF) in LCSC pre-stained with Mitotracker Red and untreated or treated with 500 nM ABT-737 for 48 h. Magnification × 60, zoom × 3, bar 20 μm. p65 ; PubMed: 28846096 Nat Cell Biol BCL-xL dependent SVEC cells were treated with ABT-737 (10 μM) +/- Q-VD-Oph (30 μM) for 1 h, immunostained for p65 and analysed by confocal microscopy. TNF (20 ng/ml) was used as positive control for p65 nuclear translocation. Scale bar represents 30μM. Representative images from three independent experiments.	26447615 25034785 28846096
Growth inhibition assay	Cell viability; PubMed: 22311987 J Biol Chem Stably transfected K562 cells were treated with increasing concentrations of ABT-737, obatoclax, or maritoclax for 24 h. Cell viability was determined by measuring intracellular ATP levels with the CellTiter Glo assay.	22311987
ELISA	IL-6 / IL-8; PubMed: 21084274 Cancer Res The secretion of IL-6 and IL-8 in PV-10 cells treated with DMSO, ABT-737 or enantiomer for 24 hours was determined by ELISA.	21084274

In vivo

In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. ^[1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. ^[2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse Fluorescence polarization assays: Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research: ^[4]	- Collapse Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114 Concentrations: 0.001-10 μM Incubation Time: 48 hours Method: SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells Dosages: 20 and 30 mg/kg Administration: For intraperitoneal (i.p.) every day (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL (122.93 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2%DMSO+40%PEG300+5%Tween80+53%ddH2O For best results, use promptly after mixing.	2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download ABT-737 SDF

Molecular Weight	813.43
Formula	C₄₂H₄₅ClN₆O₅S₂
CAS No.	852808-04-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CN(C)CCC(CSC1=CC=CC=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)[N+](=O)[O-]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommended method about reconstitution of the compound for in vivo animal study?
Answer:
For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Selective Bcl-2 Inhibitor

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
Most Potent Bcl-2 Inhibitor

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
Bcl-2 Inhibitor in Clinical Trial

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

Related Bcl-2 Products

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Venetoclax (ABT-199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Venetoclax is reported to induce cell growth suppression, apoptosis, cell cycle arrest, and autophagy in triple negative breast cancer MDA-MB-231 cells. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax (BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
(R)-(-)-Gossypol acetic acid

(R)-(-)-Gossypol (AT-101) acetic acid, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. AT-101 simultaneously triggers apoptosis and a cytoprotective type of autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

ABT-737